Bionik Laboratories (BNKL) S-1 16 Sep 19 IPO registration Financial data

Document and Entity Information

Document and Entity Information	3 Months Ended
	Jun. 30, 2019
Document and Entity Information [Abstract]
Document Type	S-1
Amendment Flag	false
Document Period End Date	Jun. 30, 2019
Entity Registrant Name	Bionik Laboratories Corp.
Entity Central Index Key	0001508381
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Current
Cash and cash equivalents	$ 530,031	$ 446,779	$ 507,311
Accounts receivable, net of allowance for doubtful accounts of $Nil (March 31, 2018 - $19,694)	1,027,012	1,523,193	212,730
Prepaid expenses and other receivables (Note 5)	1,194,727	1,355,032	433,655
Inventories (Note 6)	582,058	405,682	237,443
Due from related parties (Note 9(a))	19,068	18,585	18,897
Total Current Assets	3,352,896	3,749,271	1,410,036
Equipment (Note 7)	211,360	192,528	159,961
Technology and other assets (Note 4)	4,358,408	4,427,722	4,706,719
Goodwill (Note 3)	22,308,275	22,308,275	22,308,275
Total Assets	30,230,939	30,677,796	28,584,991
Current
Accounts Payable (Notes 9(b))	1,055,017	1,148,852	724,673
Accrued liabilities (Notes 8 and 9(b))	1,620,632	1,653,233	1,530,305
Demand Loans (Note 8)		0	51,479
Convertible Loans (Note 8(a))	954,450	0
Deferred revenue - Contract Liabilities	525,794	467,778	122,667
Shares to be issued, stock options and warrants (Note 10)		0	5,692,853
Total Current Liabilities	4,155,893	3,269,863	8,121,977
Term loan (Note 8(b))	500,000	0
Total Liabilities	4,655,893	3,269,863	8,121,977
Shareholders' Equity
Preferred Stock, par value $0.001; Authorized 10,000,000 Special Voting Preferred Stock, par value $0.001; Authorized; Issued and outstanding - 1 (March 31, 2019 - 1)
Common Shares, par value $0.001; Authorized - 500,000,000 (March 31, 2019 - 500,000,000); Issued and outstanding 3,702,398 and 156,239 Exchangeable Shares (March 31, 2019 -3,661,838 and 196,799 Exchangeable Shares)	3,858	3,858	1,664
Additional paid in capital	74,007,056	73,719,299	56,195,541
Deficit	(48,478,017)	(46,357,373)	(35,776,340)
Accumulated other comprehensive income	42,149	42,149	42,149
Total Shareholders' Equity	25,575,046	27,407,933	20,463,014
Total Liabilities and Shareholders' Equity	$ 30,230,939	$ 30,677,796	$ 28,584,991

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets [Parenthetical] - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Allowance for Doubtful Accounts Receivable, Current	$ 0	$ 0	$ 19,694
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	10,000,000	10,000,000	10,000,000
Common Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Common Stock, Shares Authorized	500,000,000	500,000,000	250,000,000
Common Stock, Shares, Issued	3,702,398	3,661,838	1,368,856
Common Stock, Shares, Outstanding	3,702,398	3,661,838	1,368,856
Common Stock, Other Shares, Issued	156,239	196,799	295,146
Common Stock, Other Shares, Outstanding	156,239	196,799	295,146
Special Voting Preferred Stock [Member]
Preferred Stock, Par Value (in dollars per share)	$ 0.001	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1	1	1
Preferred Stock, Shares Issued	1	1	1
Preferred Stock, Shares Outstanding	1	1	1

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Sales	$ 790,379	$ 501,333	$ 3,246,038	$ 987,431
Cost of Sales	336,085	253,163	1,630,166	402,665
Gross Margin	454,294	248,170	1,615,872	584,766
Operating expenses
Sales and marketing	583,732	542,659	2,339,359	1,989,837
Research and development	816,523	676,743	3,174,892	2,825,200
General and administrative	841,693	979,479	3,893,393	3,585,484
Share-based compensation expense (Note 11)	287,757	595,412	1,347,399	1,540,580
Amortization (Note 4)	69,314	71,053	278,997	323,905
Depreciation (Note 7)	23,970	17,595	69,212	89,026
Total operating expenses	2,622,989	2,882,941	11,103,252	10,354,032
Other (income) expenses
Accretion expense (Note 8)	0	134,251	3,266,918	1,937,308
Share premium			0	1,249,994
Fair Value Adjustment (Note 8)	0	44,087	(337,923)	0
Gain/Loss on mark to market re-evaluation (Note 10(c))	0	(2,048,697)	(2,048,697)	376,674
Other expense	14,296	37,420	262,596	1,297,205
Other income			(73,166)	(107,656)
Foreign exchange	(62,347)	(41,134)	(507)	102,999
Total other expenses	(48,051)	(1,874,073)	1,069,221	4,856,524
Net loss and comprehensive loss for the period	$ (2,120,644)	$ (760,698)	$ (10,556,601)	$ (14,625,790)
Loss per share - basic and diluted	$ (0.55)	$ (0.44)	$ (4.47)	$ (21.73)
Weighted average number of shares outstanding - basic and diluted	3,858,637	1,716,728	2,363,107	673,203

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Changes in Shareholders' Equity - USD ($)	Total	Convertible Debt One [Member]	Convertible Debt Two [Member]	Conversion of Promissory notes [Member]	European Promissory notes tranche One [Member]	European Promissory notes tranche Two [Member]	European Promissory Notes Tranche Three [Member]	Special Voting Preferred Stock [Member]	Special Voting Preferred Stock [Member]Convertible Debt One [Member]	Special Voting Preferred Stock [Member]Convertible Debt Two [Member]	Special Voting [Member]Convertible Debt One [Member]	Special Voting [Member]Convertible Debt Two [Member]	Special Voting [Member]European Promissory notes tranche One [Member]	Special Voting [Member]European Promissory notes tranche Two [Member]	Special Voting [Member]European Promissory Notes Tranche Three [Member]	Common Shares [Member]	Common Shares [Member]Convertible Debt One [Member]	Common Shares [Member]Convertible Debt Two [Member]	Common Shares [Member]Conversion of Promissory notes [Member]	Common Shares [Member]European Promissory notes tranche One [Member]	Common Shares [Member]European Promissory notes tranche Two [Member]	Common Shares [Member]European Promissory Notes Tranche Three [Member]	Additional Paid in Capital [Member]	Additional Paid in Capital [Member]Convertible Debt One [Member]	Additional Paid in Capital [Member]Convertible Debt Two [Member]	Additional Paid in Capital [Member]Conversion of Promissory notes [Member]	Additional Paid in Capital [Member]European Promissory notes tranche One [Member]	Additional Paid in Capital [Member]European Promissory notes tranche Two [Member]	Additional Paid in Capital [Member]European Promissory Notes Tranche Three [Member]	Deficit [Member]	Deficit [Member]Convertible Debt One [Member]	Deficit [Member]Convertible Debt Two [Member]	Deficit [Member]European Promissory notes tranche One [Member]	Deficit [Member]European Promissory notes tranche Two [Member]	Deficit [Member]European Promissory Notes Tranche Three [Member]	Comprehensive Income [Member]	Comprehensive Income [Member]Convertible Debt One [Member]	Comprehensive Income [Member]Convertible Debt Two [Member]	Comprehensive Income [Member]European Promissory notes tranche One [Member]	Comprehensive Income [Member]European Promissory notes tranche Two [Member]	Comprehensive Income [Member]European Promissory Notes Tranche Three [Member]	European Promissory Notes Tranche Three [Member]Convertible Debt One [Member]	European Promissory Notes Tranche Three [Member]Convertible Debt Two [Member]
Opening Balance at Mar. 31, 2017	$ 24,150,650															$ 645							$ 45,184,320							$ (21,076,464)						$ 42,149
Opening Balance (in shares) at Mar. 31, 2017																645,297
Warrant exercised	1,125,038															$ 33							1,125,005							0						0
Warrant exercised (in shares)																33,335
Conversion of Promissory notes	9,180,785			$ 533,556	$ 3,060,304	$ 4,244,220	$ 1,342,705						$ 0	$ 0	$ 0	$ 63			$ 63,000	$ 327	$ 453	$ 143	533,493			$ 533,493	$ 3,059,977	$ 4,243,767	$ 1,342,562	0			$ 0	$ 0	$ 0	0			$ 0	$ 0	$ 0
Conversion of Promissory notes (in shares)																			62,629	326,563	452,898	143,280
Beneficial Conversion Feature on convertible debt	1,389,129															0							1,389,129							0						0
Stock option and warrant reclassification (Notes 11 & 12)	(2,845,557)															0							(2,845,557)							0						0
Share compensation expense	1,540,580															0							1,540,580							0						0
Fair value of warrants on convertible loans	548,179															0							548,179							0						0
Loss on Warrant downround feature	0															0							74,086							(74,086)						0
Shares to be issued for services	0															0														0						0
Net loss for the year	(14,625,790)															0							0							(14,625,790)						0
Closing Balance at Mar. 31, 2018	20,463,014							$ 0								$ 1,664							56,195,541							(35,776,340)						42,149
Closing Balance (in shares) at Mar. 31, 2018								1								1,664,002
Conversion of Promissory notes								$ 0								$ 264							2,470,358							0						0
Conversion of Promissory notes (in shares)																263,639
Stock option and warrant reclassification (Notes 11 & 12)	1,173,534							0								$ 0							1,173,534							0						0
Share compensation expense	595,412							0								$ 0							595,412							0						0
Share compensation expense (in shares)																0
Net loss for the year	(760,698)							0								$ 0							0							(760,698)						0
Closing Balance at Jun. 30, 2018	23,941,884							$ 0								$ 1,928							60,434,845							(36,537,038)						42,149
Closing Balance (in shares) at Jun. 30, 2018								1								1,927,641
Opening Balance at Mar. 31, 2018	20,463,014							$ 0								$ 1,664							56,195,541							(35,776,340)						42,149
Opening Balance (in shares) at Mar. 31, 2018								1								1,664,002
Conversion of Promissory notes	13,214,092	$ 4,732,853	$ 6,010,617	$ 2,470,622					$ 0	$ 0	$ 0	$ 0				$ 264	$ 683	$ 1,247					2,470,358	$ 4,732,170	$ 6,009,370					0	$ 0	$ 0				0	$ 0	$ 0				$ 4,732,853	$ 6,010,617
Conversion of Promissory notes (in shares)																263,639	683,395	1,247,099																								683,395	1,247,099
Stock option and warrant reclassification (Notes 11 & 12)	1,173,534															$ 0							1,173,534							0						0
Share compensation expense	1,347,399							$ 0								$ 0							1,347,399							0						0
Share compensation expense (in shares)																0
Loss on Warrant downround feature	0							0								$ 0							24,432							(24,432)						0
Fair value of Anti-dilution feature	1,766,495							0								0							1,766,495							0						0
Net loss for the year	(10,556,601)							0								0							0							(10,556,601)						0
Adjustment due to 1:150 share consolidation round-up	0							0								$ 0							0							0						0
Adjustment due to 1:150 share consolidation round-up (in shares)																502
Closing Balance at Mar. 31, 2019	27,407,933							$ 0								$ 3,858							73,719,299							(46,357,373)						42,149
Closing Balance (in shares) at Mar. 31, 2019								1								3,858,637
Opening Balance at Jun. 30, 2018	23,941,884							$ 0								$ 1,928							60,434,845							(36,537,038)						42,149
Opening Balance (in shares) at Jun. 30, 2018								1								1,927,641
Share compensation expense	751,987																						751,987
Net loss for the year	(9,795,903)																													(9,795,903)
Closing Balance at Mar. 31, 2019	27,407,933							$ 0								$ 3,858							73,719,299							(46,357,373)						42,149
Closing Balance (in shares) at Mar. 31, 2019								1								3,858,637
Share compensation expense	287,757							$ 0								$ 0							287,757							0						0
Share compensation expense (in shares)																0
Net loss for the year	(2,120,644)							0								$ 0							0							(2,120,644)						0
Closing Balance at Jun. 30, 2019	$ 25,575,046							$ 0								$ 3,858							$ 74,007,056							$ (48,478,017)						$ 42,149
Closing Balance (in shares) at Jun. 30, 2019								1								3,858,637

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Operating activities
Net loss for the year	$ (2,120,644)	$ (760,698)	$ (10,556,601)	$ (14,625,790)
Adjustment for items not affecting cash
Depreciation (Note 7)	23,970	17,595	69,212	89,026
Amortization	69,314	71,053	278,997	323,905
Interest expense	13,283	36,702	255,833	1,294,005
Share based compensation expense	287,757	595,412	1,347,399	1,540,580
Shares premium			0	1,249,994
Accretion expense	0	134,251	3,266,918	1,937,308
Fair value Adjustment	0	44,087	(337,923)	0
Gain/Loss on mark to market re-evaluation	0	(2,048,697)	(2,048,697)	376,674
Allowance for doubtful accounts	0	(19,694)	(19,694)	(19,694)
Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities	(1,726,320)	(1,929,989)	(7,744,556)	(7,833,992)
Changes in non-cash working capital items
Accounts receivable	496,181	(137,756)	(1,290,769)	190,867
Prepaid expenses and other receivables	160,305	(51,793)	(921,377)	(205,608)
Due from related parties	(483)	350	312	(166)
Inventories	(176,376)	81,648	(168,239)	(9,194)
Accounts payable	(93,835)	11,468	424,179	(60,098)
Accrued liabilities	(41,434)	(402,141)	122,928	304,048
Customer advances			0	(120,762)
Deferred revenue	58,016	7,117	345,111	24,043
Net cash (used in) operating activities	(1,323,946)	(2,421,096)	(9,232,411)	(7,710,862)
Investing activities
Acquisition of equipment	(42,802)	(7,844)	(101,779)	(21,567)
Net cash (used in) investing activities	(42,802)	(7,844)	(101,779)	(21,567)
Financing activities
Proceeds on exercise of warrants			0	1,125,038
Proceeds from convertible loans	950,000	2,934,298	9,326,633	7,111,375
Repayment of Promissory notes principal			0	(200,000)
Repayment of Promissory notes interest			0	(49,505)
Repayment of Demand notes principal	0	(50,000)	(50,000)	(208,359)
Repayment of Demand notes interest	0	(2,975)	(2,975)	(79,259)
Proceeds from short-term loan	500,000	0	0	400,000
Repayment of short-term loan			0	(400,000)
Repayment of short-term loan interest			0	(3,200)
Net cash provided by financing activities	1,450,000	2,881,323	9,273,658	7,696,090
Net (decrease) in cash and cash equivalents for the period	83,252	452,393	(60,532)	(36,339)
Cash and cash equivalents, beginning of the period	446,779	507,311	507,311	543,650
Cash and cash equivalents, end of the period	$ 530,031	$ 959,704	$ 446,779	$ 507,311

NATURE OF OPERATIONS AND GOING

NATURE OF OPERATIONS AND GOING CONCERN	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Organization Consolidation And Presentation Of Financial Statements Abstract
Substantial Doubt about Going Concern [Text Block]	1. NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp. (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock-split of the common and exchangeable shares. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 333,334 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition, the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock (Note 4). On November 6, 2017, the Company approved the authorization of a common share capital share increase to 250,000,000 from 150,000,000 and on June 12, 2018, the Company approved the authorization of a common share increase to 500,000,000 from 250,000,000. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Inc., Bionik Acquisition Inc. and Bionik Canada. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These unaudited condensed consolidated interim financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA 02472. Going Concern As at June 30, 2019, the Company had a working capital deficit of $(802,997) (March 31, 2019 – working capital of $479,408) and an accumulated deficit of $(48,478,017) (March 31, 2019 $(46,357,373)) and the Company incurred a net loss and comprehensive loss of $(2,120,644) for the three month period ended June 30, 2019 (June 30, 2018 – $(760,698)). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects to raise additional funds to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these consolidated financial statements.	1. NATURE OF OPERATIONS AND GOING CONCERN The Company and its Operations Bionik Laboratories Corp., (the “Company” or “Bionik”) was incorporated on January 8, 2010 in the State of Colorado as Strategic Dental Management Corp. On July 16, 2013, the Company changed its name to Drywave Technologies Inc. (“Drywave”) and its state of incorporation from Colorado to Delaware. Effective February 13, 2015, the Company changed its name to Bionik Laboratories Corp. and reduced the authorized number of shares of common stock from 200,000,000 to 150,000,000. Concurrently, the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014. On October 29, 2018, the Company implemented at 1 for 150 reverse stock split of the common and exchangeable shares. On February 26, 2015, the Company entered into a Share Exchange Agreement and related transactions whereby it acquired Bionik Laboratories Inc., a Canadian Corporation (“Bionik Canada”) and Bionik Canada issued 333,334 Exchangeable Shares, representing a 3.14 exchange ratio, for 100% of the then outstanding common shares of Bionik Canada (the “Merger”). The Exchangeable Shares are exchangeable at the option of the holder, each into one share of the common stock of the Company. In addition, the Company issued one Special Preferred Voting Share (the “Special Preferred Share”) (Note 10). On April 21, 2016, the Company acquired all of the outstanding shares and, accordingly, all assets and liabilities of Interactive Motion Technologies, Inc. (IMT), a Boston, Massachusetts-based global pioneer and leader in providing effective robotic products for neurorehabilitation, pursuant to an Agreement and Plan of Merger (the “Merger Agreement”) dated March 1, 2016, with IMT, Hermano Igo Krebs, and Bionik Mergerco Inc., a Massachusetts corporation and the Company’s wholly owned subsidiary (Bionik Mergerco). The merger agreement provided for the merger of Bionik Mergerco with and into IMT, with IMT surviving the merger as the Company’s wholly owned subsidiary. In return for acquiring IMT, IMT shareholders received an aggregate of 157,667 shares of the Company’s common stock (Note 4). On November 6, 2017, the Company approved the authorization of a common share capital share increase to 250,000,000 from 150,000,000 and on June 12, 2018, the Company approved the authorization of a common share increase to 500,000,000 from 250,000,000. References to the Company refer to the Company and its wholly owned subsidiaries, Bionik Inc., Bionik Acquisition Inc. and Bionik Canada. The Company is a global pioneering robotics company focused on providing rehabilitation solutions to individuals with neurological disorders, specializing in designing, developing and commercializing cost-effective physical rehabilitation technologies, prosthetics, and assisted robotic products. The Company strives to innovate and build devices that can rehabilitate and improve an individual’s health, comfort, accessibility and quality of life through the use of advanced algorithms and sensing technologies that anticipate a user’s every move. These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“US GAAP”), which contemplates continuation of the Company as a going concern, which assumes the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. The Company’s principal offices are located at 483 Bay Street, N105, Toronto, Ontario, Canada M5G 2C9 and its U.S. address is 80 Coolidge Hill Road, Watertown, MA 02472. Going Concern As at March 31, 2019, the Company had a working capital surplus of $479,408 (working capital deficit as at March 31, 2018, of $(6,711,941)) and an accumulated deficit of $46,357,373 (March 31, 2018 - $35,776,340) and the Company incurred a net loss and comprehensive loss of $10,556,601 for the year ended March 31, 2019 (March 31, 2018 - $(14,625,790)). There is no certainty that the Company will be successful in generating sufficient cash flow from operations or achieving and maintaining profitable operations in the future to enable it to meet its obligations as they come due and consequently continue as a going concern. The Company will require additional financing this year to fund its operations and it is currently working on securing this funding through corporate collaborations, public or private equity offerings or debt financings. Sales of additional equity securities by the Company would result in the dilution of the interests of existing stockholders. There can be no assurance that financing will be available when required. In the event that the necessary additional financing is not obtained, the Company would reduce its discretionary overhead costs substantially or otherwise curtail operations. The Company expects the forgoing, or a combination thereof, to meet the Company’s anticipated cash requirements for the next 12 months; however, these conditions raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments to reflect the possible future effects on recoverability and reclassification of assets or the amounts and classification of liabilities that may result from the outcome of this uncertainty. All adjustments, consisting only of normal recurring items, considered necessary for fair presentation have been included in these consolidated financial statements.

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Disclosure Text Block [Abstract]
Basis of Presentation [Text Block]	2. BASIS OF PRESENTATION During the 2019 fiscal year, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Bionik’s common stock and exchangeable shares at a ratio up to one-to-one hundred and fifty. On October 29, 2018, the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. All owners of record on October 29, 2018 received one issued and outstanding share of Bionik common stock or exchangeable share in exchange for one hundred and fifty issued and outstanding shares of Bionik common stock or Bionik exchangeable stock. No fractional shares were issued in connection with the reverse stock split. All fractional shares created by the one-for-one hundred and fifty reverse split were rounded up to the next whole share. The reverse stock split had no impact on the par value per share of Bionik common stock, which remains at $0.001. All current and prior period amounts related to shares, share prices and earnings per share, presented in the Company’s consolidated financial statements and the accompanying Notes contained in this Quarterly Report on Form 10‑Q have been restated to give retrospective presentation for the reverse stock split.	2. BASIS OF PRESENTATION During the fiscal year, holders of the common stock and exchangeable shares of the Company approved, through a majority shareholder vote, an amendment to the Company’s Amended and Restated Certificate of Incorporation authorizing the Board of Directors to effect a reverse stock split of Bionik’s common stock and exchangeable shares at a ratio up to one-to-one hundred and fifty. On October 29, 2018, the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis. 0.001

SIGNIFICANT ACCOUNTING POLICIES

SIGNIFICANT ACCOUNTING POLICIES	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
SIGNIFICANT ACCOUNTING POLICIES
Significant Accounting Policies [Text Block]	3. SIGNIFICANT ACCOUNTING POLICIES Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10‑K for the year ended March 31, 2019. The interim disclosures generally do not repeat those in the annual statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The changes in accounting policies in the Company’s unaudited condensed consolidated interim financial statements from the March 31, 2019 audited financial statements are described below. Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014‑09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014‑09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014‑09, as amended, is effective for the Company in the interim period ended June 30, 2019. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU‑2014‑1 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In November 2015, the FASB issued ASU No. 2015‑17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015‑17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU‑2015‑17 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016‑01 Financial Instruments - Overall (Subtopic 825‑10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825‑10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU 2016‑01 for the year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016‑02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company has adopted ASU 2016‑02 and it did not have a material effect on the consolidated statement of financial position and consolidated statement of operations. In August 2016, the FASB issued ASU 2016‑15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016‑15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU 2016‑15 for the fiscal year ended March 31, 2019 and it did not have material effect on the consolidated financial position or on the consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted ASU 2017-09 during the year ended March 31, 2019 and it did not have a material effect on the consolidated financial statements and the consolidated results of operations. Recently Issued In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated financial position or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2017-04 will have on the consolidated statement of financial position and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2016-13 will have on the consolidated statement of financial position and consolidated statement of operations. Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the condensed consolidated interim balance sheets and amounted to $168,000 at June 30, 2019 (March 31, 2019 - $143,500). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $26,911 of expenses related to warranty expenses and recorded this expense in cost of goods sold for the three-month period ended June 30, 2019 (June 30, 2018 – $10,108).	3. SIGNIFICANT ACCOUNTING POLICIES Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU-2014-1 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU 2016-01 for the year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU 2016-15 for the fiscal year ended March 31, 2019 and it did not have material effect on the consolidated financial position or on the consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted ASU 2017-09 during the year ended March 31, 2019 and it did not have a material effect on the consolidated financial statements and the consolidated results of operations. Recently Issued In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated financial position or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2017-04 will have on the consolidated statement of financial position and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2016-13 will have on the consolidated statement of financial position and consolidated statement of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated statement of financial position and consolidated statement of operations. Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at actual cost, on the first-in first-out basis. The Company only has finished goods inventory recoded based on actual cost from outsourced manufacturing partner. Revenue Recognition The Company has adopted ASU-2014-9 with initial application date of April 1, 2018. The Company adopted the new standard using the modified retrospective transition method. The updated accounting policies and the impact on the consolidated audited financial statements and additional disclosures are as follows: The Company determines revenue through the following steps: a) identification of the contract with the customer; b) identification of the performance obligations in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when or as the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in the contract with the customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by customer that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. The Company defers revenue from extended warranty sales and recognizes them over the period of extended warranty and from training services when the training is provided. In the comparative period, the revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there were significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods. Allowance for doubtful accounts The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated credit risk by supplying products to customers with pre-approved capital expenditure budgets or rental credit, and by actively pursuing past due accounts. An allowance for doubtful accounts is estimated and recorded based on management’s assessment of the credit history with the customer and the current relationships with them. On this basis management has determined that an allowance for doubtful accounts of $Nil and $ 19,694 Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the consolidated balance sheets and amounted to $143,500 at March 31, 2019 (March 31, 2018 - $64,957). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $84,038 of expenses related to warranty expenses and recorded this expense in cost of goods sold for the year ended March 31, 2019 (March 31, 2018 - $Nil). Foreign Currency Translation The functional and presentation currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit and loss. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction. Equipment Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows: Computer and Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum Assets under capital lease Life of lease (60 months) Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates based on management’s best knowledge of current events and actions of the Company may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets, share based compensation, warranty accruals, accretion, fair value adjustment and fair value determination of warrants. Actual results could differ from these estimates. Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued liabilities, due from related parties, demand loans, convertible loans and promissory note payable approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year. Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segment are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Approximately 99 148,618 120,910 43,910 39,051 Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash on deposit with Canadian and US banks. Research and Development The Company is engaged in research and development work. Research and development costs are charged to operating expenses of the Company as incurred. Share based compensation At grant date share-based compensation is valued using the Black-Scholes option pricing model based on key assumptions determined by the Company. The value is recognized based on the straight- line method during the vesting period or based on the fulfillment of predetermined milestones in case of performance-based vesting. Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations. Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants were excluded from the computation of diluted loss per share because their effect was anti-dilutive. Impairment of Long-Lived Assets The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale, they are recorded at the lower of the carrying amount or the expected sales price less costs to sell. Goodwill and Indefinite Lived Intangible Assets The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill and indefinite lived intangible assets, consisting of the trademarks acquired (Note 4), are assessed for impairment annually, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill or indefinite lived intangible assets. The qualitative factors used in the analysis include microeconomic conditions, industry and market conditions, cost factors, overall financial performance and other relevant entity specific events. The Company performs impairment tests using a fair value approach when necessary. None of the Company’s goodwill or indefinite lived intangibles was impaired as of March 31, 2019. Accordingly, no impairment loss has been recognized in the year ended March 31, 2019.

TECHNOLOGY AND OTHER ASSETS

TECHNOLOGY AND OTHER ASSETS	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
TECHNOLOGY AND OTHER ASSETS
Intangible Assets Disclosure [Text Block]	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three months ended June 30, 2019, and the year ended March 31, 2019: Amortization Expenses Value at Expenses Value at period (years) Value acquired March 31, 2019 March 31, 2019 June 30, 2019 June 30, 2019 Intangible assets acquired $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,126 911,440 33,522 877,918 Trademark Indefinite 2,505,907 — 2,505,907 — 2,505,907 Customer relationships 10 1,431,680 143,206 1,010,375 35,792 974,583 Non compete agreement 2 61,366 1,739 — — — Assembled workforce 1 275,720 — — — — 5,580,704 278,997 4,427,722 69,314 4,358,408 The aggregate amortization expense for the technology and other assets was $69,314 and $71,053 at June 30, 2019 and 2018, respectively.	4. TECHNOLOGY AND OTHER ASSETS The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the year ended March 31, 2019: Amortization period (years) Value acquired Expense March 31, 2018 Value at March 31, 2018 Expenses March 31, 2019 Value at March 31, 2019 Intangible assets acquired $ $ $ $ $ Patents and exclusive Licence Agreement 9.74 1,306,031 134,126 1,045,530 134,090 911,440 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 143,168 1,010,375 Non compete agreement 2 61,366 30,709 1,739 1,739 - Assembled workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 278,997 4,427,722 The aggregate amortization expense for the technology and other assets was $1,152,982 and $873,985 at March 31, 2019 and 2018 respectively.

PREPAID EXPENSES AND OTHER RECE

PREPAID EXPENSES AND OTHER RECEIVABLES	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
PREPAID EXPENSES AND OTHER RECEIVABLES
Prepaid Expense And Other Receivables [Text Block]	5. PREPAID EXPENSES AND OTHER RECEIVABLES June 30, March 31, 2019 2019 $ $ Prepaid expenses and other receivables 75,780 92,170 Prepaid inventory 939,593 1,144,392 Prepaid insurance 160,787 66,320 Sales taxes receivable (i) 18,567 52,150 1,194,727 1,355,032 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	5. PREPAID EXPENSES AND OTHER RECEIVABLES March 31, 2019 March 31, 2018 $ $ Prepaid expenses and other receivables 92,170 86,957 Prepaid inventory 1,144,392 301,104 Prepaid insurance 66,320 36,497 Sales taxes receivable (i) 52,150 9,097 1,355,032 433,655 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES

INVENTORIES	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
INVENTORIES
Inventory Disclosure [Text Block]	6. INVENTORIES June 30, March 31, 2019 2019 Finished Goods 582,058 405,682 During the three month period ended June 30, 2019, the Company expensed $299,795 in inventory as cost of goods sold (June 30, 2018 - $237,000). The Company no longer maintains a raw materials inventory as it has outsourced its manufacturing to a third party.	6. INVENTORIES March 31, 2019 March 31, 2018 $ $ Raw Materials - 237,443 Finished Goods 405,682 - 405,682 237,443 For the year ended March 31, 2019, $ 62,589 .

EQUIPMENT

EQUIPMENT	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
EQUIPMENT
Property, Plant and Equipment Disclosure [Text Block]	7. EQUIPMENT Equipment consisted of the following as at June 30, 2019 and March 31, 2019: June 30, 2019 March 31, 2019 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 286,855 248,357 38,498 286,855 243,346 43,509 Furniture and fixtures 36,795 29,999 6,796 36,795 29,648 7,147 Demonstration equipment 314,417 164,363 150,054 271,615 147,257 124,358 Manufacturing equipment 88,742 86,353 2,389 88,742 86,230 2,512 Tools and parts 11,422 7,007 4,415 11,422 6,779 4,643 Assets under capital lease 23,019 13,811 9,208 23,019 12,660 10,359 761,250 549,890 211,360 718,448 525,920 192,528 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the three-month period ended June 30, 2019 was $23,970 (June 30, 2018 – $17,595).	7. EQUIPMENT Equipment consisted of the following as at March 31, 2019 and March 31, 2018: March 31, 2019 March 31, 2018 Cost Accumulated Depreciation Net Cost Accumulated Depreciation Net $ $ $ $ $ $ Computers and electronics 286,855 243,346 43,509 256,505 223,750 32,755 Furniture and fixtures 36,795 29,648 7,147 36,795 28,051 8,744 Demonstration equipment 271,615 147,257 124,358 200,186 105,441 94,745 Manufacturing equipment 88,742 86,230 2,512 88,742 85,668 3,074 Tools and parts 11,422 6,779 4,643 11,422 5,741 5,681 Assets under capital lease 23,019 12,660 10,359 23,019 8,057 14,962 718,448 525,920 192,528 616,669 456,708 159,961 Equipment is recorded at cost less accumulated depreciation. Depreciation expense during the year ended March 31, 2019 was $69,212 (March 31, 2018 - $89,026).

NOTES PAYABLE

NOTES PAYABLE	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
NOTES PAYABLE
Debt Disclosure [Text Block]	8. NOTES PAYABLE (a) Convertible Loans Payable During the three months ended June 30, 2019, the Company received loans from new and existing investors totaling $950,000 pursuant to an up to $9,000,000 convertible note offering. The convertible notes bear interest at a fixed rate of 1% per month and will be payable, along with the principal amount, on the earlier of (the "Maturity Date"): (a) March 30, 2020 and (b) the consummation of the offering, provided that the Company raises in one or more tranches aggregate gross proceeds of no less than US$9,000,000. The convertible notes will be convertible into equity of the Company upon the following events on the following terms: · On the Maturity Date, the outstanding principal and accrued and unpaid interest under the convertible notes will be converted into shares of common stock at a conversion price of US$6.80 per share (the “Conversion Price”). · Upon a change of control transaction prior to the Maturity Date, the outstanding principal and accrued and unpaid interest under the convertible notes would, at the election of the holders of a majority of the outstanding principal of the loans under the offering, be either (i) payable upon demand as of the closing of such change of control transaction or (ii) convertible into shares of the Company’s common stock immediately prior to such change of control transaction at a price per share equal to the lesser of (x) the Conversion Price, or (y) the per share consideration to be received by the holders of the common stock in such change of control transaction. In the event the Company raises capital through the sale of Common Stock for cash during the period ending on the three year anniversary of the earliest issuance date of the convertible notes, and the price per share thereof (the “ Offering Price ”) is less than the original Conversion Price, then in such event the Company shall issue to all convertible loan holder at, at no further cost, additional shares of common stock equal to the number of conversion shares the holders would have received upon conversion if the Conversion Price equaled the Offering Price, less the number of shares of conversion shares actually issued on or as of the Maturity Date. Since the Company has early adopted ASU 2017-11, the anti-dilution protection clause does not contribute to the conversion feature to be a derivative liability. The interest accrued on these convertible loans for the three months ended June 30, 2019 was $4,450. (b) Term Loans During the quarter ended June 30, 2019, an affiliate of one of the Company’s major shareholders who is also a director provided a loan of $500,000. This loan bears interest at a fixed rate of 1% per month and is to be repaid on the earlier of May 8, 2021, the date of receipt of an aggregate of $10,000,000 in gross proceeds from the sale of the Company’s securities subsequent to the issue date of the loan or the date of a change of control of the Company. The interest accrued as at June 30, 2019 was $8,833 (June 30, 2018 - $Nil).	8. NOTES PAYABLE (a) Demand Note payable The Company had an outstanding note payable (“Notes”) of $Nil at March 31, 2019 ($51,479 – March 31, 2018), which was acquired from IMT on April 21, 2016. The Note and interest was repaid during the year ended March 31, 2019. Balance March 31, 2017 330,600 Accrued interest 8,497 Repayment (287,618 ) Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment (52,975 ) Balance, March 31, 2019 $ - Interest expense incurred on the Note totaled $1,496 for the year ended March 31, 2019 (March 31, 2018 - $8,497), which was included in accrued liabilities until it was paid off. (b) Promissory Notes Payable In February 2014, the Company borrowed $200,000 for an existing investor under the terms of a secured promissory note (“Promissory Note”). The Promissory Note bears interest at a simple interest rate equal to 10% per annum and interest is payable quarterly. Interest expenses incurred on the Promissory Note totaled $Nil for year ended March 31, 2019 (March 31, 2018 - $12,957). The Promissory Note was paid in full during the year ended March 31, 2018. (c) Short term Loan In December 2017, a company controlled by a Board member made a short-term loan to the Company of $400,000 with interest at 1.5% per month. Interest expenses totaled $Nil for the year ended March 31, 2019 (March 31, 2018 -$3,200). The Company repaid this note with interest of $3,200 during the year ended March 31, 2018. (d) Convertible Loans Payable (1) In December 2016, several shareholders of the Company agreed to advance the Company $1,500,000 of convertible notes in three tranches: $500,000 upon origination of the convertible loans and $500,000 on each of January 15, 2017 and February 15, 2017. A further $500,000 was advanced in March 2017 to bring the total of these convertible loans to approximately $2,000,000. The convertible loans bore interest at 6% until the original due date of March 31, 2017 and $17,488 was accrued and expensed as interest on these loans for the year ended March 31, 2017. The convertible loans contain the following terms: convertible at the option of the holder at the price of the equity financing or payable on demand upon the completion of an equity financing greater than $5,000,000; automatically convertible at the price of the equity financing upon completion of an equity financing between $3,500,000 and $5,000,000; if no such equity financing is completed by November 15, 2017, then the loans shall become secured by a general security agreement over all assets of the Company; and, upon a change in control would either be payable on demand or convertible at the lesser of a price per share equal to that received by the parties in the change in control transaction or the market price of the shares. These conversion features were analyzed and determined to be contingent conversion features, accordingly, until the triggering event no beneficial conversion feature is recognized. On August 14, 2017, the Company entered into an amendment to these convertible loans, whereby the interest was changed to a fixed rate of 12% per year from April 1, 2017 to August 14, 2017, and 3% per month from August 14, 2017 to maturity, which was extended to the earlier of March 31, 2018 or consummation of a qualified financing. The conversion feature was modified to contain the following terms: upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of $7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to 25% of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) $0.25. Further, the Company issued warrants to these debt holders amounting to 20% of the aggregate principal of the convertible loans divided by the exercise price, which would be determined as the lowest of a new round stock in a qualified financing, the average volume weighted average price for the sixty trading days prior to January 31, 2018 or $0.25. The warrants have a term of five years. These amendments were treated as an extinguishment of the original debt; however, there was no gain or loss recognized and the new and amended debts were recognized as shown below. An additional $2,999,975 was received from these shareholders during the year ended March 31, 2018 for a total of $4,999,975. For the year ended March 31, 2018, an additional $1,037,067 of interest was accrued and expensed on these convertible loans. The Company has recognized a discount against the convertible loans for the relative fair value of the warrants and is accreting the discount using the effective interest rate method. The assumptions used in valuing the warrants using the binomial valuation model five Balance, March 31, 2016 $ - Additional principal investment 2,000,000 Accrued Interest 17,488 Balance, March 31, 2017 2,017,488 Additional principal investment 2,999,975 Fair value of warrants (548,178 ) Accretion expense 548,178 Accrued Interest 1,037,067 Conversion of principal and interest (6,054,530 ) Balance, March 31, 2018 and March 31, 2019 $ - (2) In May 2017, the Company’s Chinese joint venture partners loaned the Company $500,000 at an interest rate of 8% convertible into the Company’s common shares upon a capital raise (“Qualified Financing”) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on the conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion. Balance, March 31, 2017 $ - Additional principal investment 500,000 Accrued Interest 33,556 Conversion of principal and interest (533,556 ) Balance, March 31, 2018 and March 31, 2019 $ - (3) In December 2017, investors of the Company advanced funds under a new convertible loan offering. These convertible loans bear interest at a fixed rate of 3% per month until the earlier of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than $7,000,000 and up to $14,000,000 raised in one or more tranches. On the maturity date, without any action on the part of the Holder, the outstanding principal and accrued and unpaid interest under the notes will be converted into shares of new round stock based upon a (15%) discount to the lesser of (i) (A) the VWAP average of the last 30 days ending on the closing of the qualified financing (or, in the event of multiple closings, the lowest VWAP average of the last 30 days ending on each closing of a qualified financing) in the event of a maturity date referred to in clause (b) of the definition thereof, or (B) the VWAP average of the last 30 days before the maturity date in the event of a maturity date referred to in clause (a) of the definition thereof, and (ii) ($0.18) In January 2018, the terms of the new convertible loan offering were amended to extend the maturity date until March 31, 2018 and in March 2018 the terms of the loans were amended to change the definition of qualified financing as gross proceeds of no less than $2,000,000 and up to $14,000,000 raised in one or more tranches. $3,611,400 was received from these investors during the twelve months ended March 31, 2018 and $201,928 of interest was accrued and expensed on these convertible loans for the twelve months ended March 31, 2018. Balance, March 31, 2017 - Additional principal investment 3,611,400 Accrued Interest 201,928 Conversion of principal and interest (3,813,328 ) Balance, March 31, 2018 and March 31, 2019 $ - (4) Conversion of Notes Payable March 31, 2018 Principal Interest Premium Total Conversion Amount Beneficial Conversion Feature Number of Shares Converted Convertible Notes Payable (December 2016 to December 2017) $ 4,999,975 $ 1,054,555 $ 1,249,994 $ 7,304,523 $ 762,301 779,461 Chinese Convertible Loan $ 500,000 $ 33,556 - $ 533,556 $ 76,230 62,629 Convertible Notes Payable (December 2017 to March 2018) $ 3,611,400 $ 201,928 - $ 3,813,328 $ 550,598 406,918 Total $ 9,111,375 $ 1,290,039 $ 1,249,994 $ 11,651,407 $ 1,389,129 1,249,008 (5) Between April 1, 2018 and July 20, 2018, the Company received loans totaling $4,708,306 (which is inclusive of $31,673 that was capitalized interest which carried an interest rate of 1% per month) and of which $2,297,928 came from related parties. $4,732,853 of the loans and accrued and unpaid interest thereon were converted into 683,396 common shares as of July 20, 2018 at a 10% discount to the 30-day volume weighted average price (“VWAP”) of the Company’s stock price. The tables below reflect the fair value and anti-dilution features of the convertible loans, which resulted in accretion expense related to the loans: At issuance At July 20, 2018 Principal Conversion feature fair value Ending Conversion Anti-dilution Fair value of debt Accretion expense Interest balance before conversion Convertible promissory note $ 4,708,306 $ 406,744 $ 1,697,674 $ 2,603,888 $ 2,104,418 $ 24,547 $ 4,732,853 Conversion Anti-dilution Total Conversion feature fair value At Issuance $ 406,744 $ 1,697,674 $ 2,104,418 Fair value adjustment $ (406,744 ) $ 68,821 $ (337,923 ) Balance allocated to equity on conversion $ - $ (1,766,495 ) $ (1,766,495 ) Ending balance at March 31, 2019 $ - $ - $ - (6) Between October 1, 2018 and March 31, 2019, the Company received $4,650,000 in new convertible loans (“New Loans”), which carry an interest rate of 1% per month and of which $1,050,000 came from related parties. The schedules below reflect the accretion expense of $1,162,500 and interest expense of $198,117 being expensed in relation to the New Loans for the year ended March 31, 2019. The loan and accrued interest of $ 6,010,617 20 At issuance At March 28, 2019 Principal Accretion expense Interest Ending Balance Convertible promissory note $ 4,650,000 $ 1,162,500 $ 198,117 $ 6,010,617 (7) During the year ended March 31, 2019, the Company received loans totaling $9,326,633 ( 1% per month and of which $3,347,928 came from related parties. An accretion expense of $3,266,918 and a fair value adjustment of $337,923 was expensed for the year ended March 31, 2019 (March 31, 2018 - $1,937,308 accretion and $Nil and $Nil fair value adjustment).

RELATED PARTY TRANSACTIONS AND

RELATED PARTY TRANSACTIONS AND BALANCES	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
RELATED PARTY TRANSACTIONS AND BALANCES
Related Party Transactions Disclosure [Text Block]	9. RELATED PARTY TRANSACTIONS AND BALANCES (a) Due from related parties At June 30, 2019 there was an outstanding loan to the Chief Technology Officer ("CTO") of the Company of $19,068 (March 31, 2019 – $18,585). The loan has an interest rate of 1% until June 30, 2018 and 2% after based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the period ended June 30, 2019, the Company accrued interest receivable in the amount of $90 (March 31, 2019 – $353); the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. (b) Accounts payable and accrued liabilities As at June 30, 2019, $258,737 (March 31, 2019 – $229,473) was owing to the CEO of the Company; $14,532 (March 31, 2019 – $14,851) was owing to the Chief Technology Officer; $33,432 (March 31, 2019 – $33,387) was owing to the Chief Financial Officer ("CFO"), $28,025 (March 31, 2019 - $28,025) was owing to the former Chief Commercial Officer ("CCO"), all related to severance, bonuses and business expenses.	9. RELATED PARTY TRANSACTIONS AND BALANCES (a) Due from related parties An outstanding loan to the Chief Technology Officer (“CTO”) of the Company is for $18,585 (March 31, 2018 - $18,897). The loan had an interest rate of 1% until March 31, 2018 and 2% after based on the Canada Revenue Agency’s prescribed rate for such advances and is denominated in Canadian dollars. During the year ended March 31, 2019, the Company accrued interest receivable in the amount of $353 (March 31, 2018 – $590); the remaining fluctuation in the balance from the prior year is due to changes in foreign exchange. (b) Accounts payable and accrued liabilities As at March 31, 2019, $229,473 (March 31, 2018 - $208,567) was owing to the CEO of the Company; $14,851 (March 31, 2018 – $135,039) was owing to the Chief Technology Officer; $33,387 (March 31, 2018 - $116,624) was owing to the Chief Financial Officer (“CFO”), $28,025 was owing to the Chief Commercial Officer (“CCO”), and $Nil (March 31, 2018 – $587,019) was owing to the former CEO, all related to severance, bonuses and business expenses.

SHARE CAPITAL

SHARE CAPITAL	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
SHARE CAPITAL
Stockholders' Equity Note Disclosure [Text Block]	10. SHARE CAPITAL June 30, 2019 March 31, 2019 Number of Number of shares $ shares $ Exchangeable Shares Balance beginning of year 196,799 197 295,146 295 Converted into common shares (a) (40,560) (41) (98,347) (98) Balance at end of year 156,239 156 196,799 197 Common Shares Balance at beginning of the year 3,661,838 3,661 1,368,856 1,369 Shares issued to exchangeable shareholders (a) 40,560 41 98,347 98 Shares issued on conversion of loans — — 2,194,133 2,194 Share consolidation rounding adjustment — — 502 — Balance at end of the year 3,702,398 3,661 3,661,838 3,661 TOTAL SHARES 3,858,637 3,858 3,858,637 3,858 (a) During the quarter ended June 30, 2019, 40,560 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2019 – 98,347 shares) On October 29, 2018, the Company completed a one-for-one hundred and fifty (1:150) reverse stock consolidation that has been reflected in all shares and per share amounts, warrants and options. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation and is not convertible into shares of common stock of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement and the Special Voting Preferred Share will be automatically cancelled.	10. SHARE CAPITAL March 31, 2019 March 31, 2018 Number of shares $ Number of shares $ Exchangeable Shares Balance beginning of year 295,146 295 319,396 319 Converted into common shares (d) (98,347 ) (98 ) (24,250 ) (24 ) Balance at end of year 196,799 197 295,146 295 Common Shares Balance at beginning of the year 1,368,856 1,369 325,901 326 Shares issued to exchangeable shareholders (d) 98,347 98 24,250 24 Shares issued on conversion of loans (b) (c) 2,194,133 2,194 985,370 986 Warrants exercised (a) - - 33,335 33 Share consolidation rounding adjustment 502 - - - Balance at end of the year 3,661,838 3,661 1,368,856 1,369 TOTAL SHARES 3,858,637 3,858 1,664,002 1,664 (a) During the year ended March 31, 2018, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $37.50 per share, and as a result, 33,335 common shares were issued for net proceeds of $1,125,038 (Note 12). (b) During the year ended March 31, 2018, the Company converted $9,058,708 of notes payable and interest into 985,370 common shares. Under the terms of this conversion the remaining $1,342,705 of principal and interest was required to be converted into 263,639 common shares, but they were unable to be issued as a result of the Company not having enough authorized shares. The $2,470,622 value of these shares at March 31, 2018 has been classified as a liability until the common shares can be issued. In addition, there was a $376,674 loss recorded in the year connected to the difference of the $2,847,296 market value of the shares at March 31, 2018 and the value of these shares which resulted on the conversion of notes payable, the exercise price of which was based on a 30-day VWAP. The fair value of these shares ($2,847,296), outstanding warrants ($1,394,164) and options ($1,451,393) at March 31, 2018 represented the $5,692,853 liability on the Company’s balance sheet. (c) During the year ended March 31, 2019, after the increase of the number of authorized shares to 500,000,000, the company issued the outstanding 263,639 common shares related to the March 31, 2018 promissory note conversion. In addition, there was a $2,048,697 gain recorded in the year connected to the difference of the market value of the shares, outstanding options and warrants at March 31, 2018 and their value at June 12, 2018, the time of the authorized share increase and share issuance. On July 20, 2018 the Company converted $4,708,306 of notes payable and interest into 683,395 common shares and on March 28, 2019 the Company converted $4,848,117 of notes payable and interest into 1,247,099 common shares. (Note 8) (d) During the year ended March 31, 2019, 98,347 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250 shares) (e) On October 29, 2018, the Company completed a one-for-one hundred and fifty to one (1:150) reverse stock consolidation that has been reflected in all shares and per share amounts, warrants and options. Special Voting Preferred Share In connection with the Merger (Note 1), on February 26, 2015, the Company entered into a voting and exchange trust agreement (the “Trust Agreement”). Pursuant to the Trust Agreement, the Company issued one Special Voting Preferred Share to the Trustee, and the parties created a trust for the Trustee to hold the Special Voting Preferred Share for the benefit of the holders of the Exchangeable Shares (the “Beneficiaries”). Pursuant to the Trust Agreement, the Beneficiaries will have voting rights in the Company equivalent to what they would have had, had they received shares of common stock in the same amount as the Exchangeable Shares held by the Beneficiaries. In connection with the Merger and the Trust Agreement, effective February 20, 2015, the Company filed a certificate of designation of the Special Voting Preferred Share (the “Special Voting Certificate of Designation”) with the Delaware Secretary of State. Pursuant to the Special Voting Certificate of Designation, one share of the Company’s blank check preferred stock was designated as Special Voting Preferred Share. The Special Voting Preferred Share entitles the Trustee to exercise the number of votes equal to the number of Exchangeable Shares outstanding on a one-for-one basis during the term of the Trust Agreement. The Special Voting Preferred Share is not entitled to receive any dividends or to receive any assets of the Company upon liquidation and is not convertible into shares of common stock of the Company. The voting rights of the Special Voting Preferred Share will terminate pursuant to and in accordance with the Trust Agreement and the Special Voting Preferred Share will be automatically cancelled.

STOCK OPTIONS

STOCK OPTIONS	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
STOCK OPTIONS
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On April 26, 2016, the Company issued 1,667 options to an employee with an exercise price of $150.00 per share that will vest over three years at the anniversary date. The grant fair value was $213,750. During the quarter ended June 30, 2019 $3,431 (June 30, 2018 - $17,813) was recognized as stock compensation expense. On February 6, 2017, the Company issued 2,667 options to an employee with an exercise price of $105.00 per share that will vest over three years at the anniversary date. The grant fair value was $245,200. During the quarter ended June 30, 2019 $20,433 (June 30, 2018 – $20,433) of stock compensation expense was recognized. On September 1, 2017, the Company granted 81,436 options at $24.15 per share equally to an executive officer and a consultant, who is now the Chairman of the Company. 27,148 options have vested and 50% of the remaining options vest on performance being met and 50% vest annually over 5 years for the CEO, for our Chairman the options vest over 5 years. The grant date fair value was $1,832,304 and $57,259 is the current expense for the quarter ended June 30, 2019 (June 30, 2018 - $38,173). On January 24, 2018, the Company granted 24,267 options at $23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021. 7,334 options were cancelled for the year ended March 31, 2019 and 778 for the three-month period ended June 30, 2019. The grant fair value was $491,036 and $28,554 is the current stock compensation expense for the year ended June 30, 2019 (June 30, 2018 - $39,703). On April 30, 2018, the Company granted to an executive officer, 40,000 options with an exercise price of $9.74 that vest immediately with a 10‑year expiry. These options were valued using the Black Scholes model and the following inputs were used: expected life 10 years, expected volatility 114% and a risk-free rate of 1.59%. As these options vested immediately as of the grant date and $363,714 of stock compensation expense was recorded for the year ended March 31, 2019. On June 11, 2018, the Company granted to a sales executive officer, 5,000 options with an exercise price of $6.93 per share that vest over three years from the anniversary of the grant and expire in 7 years. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk -free rate of 1.59%. The grant fair value was $30,341 and $1,686 of stock compensation was recognized for quarter ended June 30, 2019 (June 30, 2018 - $562). This executive left the Company this quarter and all 5,000 options were cancelled, as they had not vested. On May 31, 2019 169,882 options were issued to employees and directors of the Company with an exercise price of $3.16 per share that vest over 1 year and 6 months, one third immediately vest and in two 6-month periods and expire in 7 years. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $453,585 and $176,394 of stock compensation was recognized for quarter ended June 30, 2019. During the quarter ended June 30, 2019, the Company recorded $287,757 in share-based compensation related to the vesting of stock options (June 30, 2018 – $595,412). The following is a summary of stock options outstanding and exercisable as of June 30, 2019: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 105.000 2,667 06-Feb-24 1,778 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 485 30-Sep-24 485 157.500 1,876 30-Sep-24 1,876 24.150 81,436 01-Sep-27 27,148 23.250 15,656 24-Jan-25 5,867 9.735 40,000 19-Apr-28 40,000 3.16 169,882 31-May-26 56,627 344,989 166,768 The weighted-average remaining contractual term of the outstanding options is 6.49 years (June 30, 2018 – 7.89 years) and for the options that are exercisable the weighted average is 6.36 years (June 30, 2018 - 7.38 years).	11. STOCK OPTIONS The purpose of the Company’s equity incentive plan, is to attract, retain and motivate persons of training, experience and leadership to the Company, including their directors, officers and employees, and to advance the interests of the Company by providing such persons with the opportunity, through share options, to acquire an increased proprietary interest in the Company. Options or other securities may be granted in respect of authorized and unissued shares, provided that the aggregate number of shares reserved for issuance upon the exercise of all options or other securities granted under the Plan shall not exceed 15% of the shares of common stock and Exchangeable Shares issued and outstanding (determined as of January 1 of each year). Optioned shares in respect of which options are not exercised shall be available for subsequent options. On November 24, 2015, the Company issued 4,334 options granted to employees that vest at an exercise price of $183.00 over three years at the anniversary date. The grant date fair value of the options was $694,384. During the year ended March 31, 2016, 1,667 options were cancelled. During the year ended March 31, 2019, $92,585, (March 31, 2018 -$142,438) in stock compensation expense was recognized and these options are now fully expensed. On December 14, 2015, the Company issued 16,634 options granted to employees, directors and consultants at an exercise price of $150 that vest over three years at the anniversary date. The grant date fair value of the options was $1,260,437. In years previous to March 31, 2018, 434 options were cancelled. For the year ended March 31, 2019 1,889 options were cancelled (March 31, 2018 - 2,912), $105,121, (March 31, 2018 - $479,315) of stock compensation expense was recognized and these options are now fully expensed. On April 21, 2016, the Company issued 20,000 stock options to employees of Bionik Inc., the Company’s wholly-owned subsidiary (formerly IMT) in exchange for 3,895,000 options that existed before the Company purchased IMT, of which 6,667 have an exercise price of $37.50 per share, 6,667 have an exercise price of $142.50 per share and 6,666 have an exercise price of $157.50 per share. The grant date fair value of vested options was $2,582,890 and has been recorded in fiscal 2016, $Nil (March 31, 2018 -$29,524) has been recognized as stock compensation expense for the year ended March 31, 2019. These options are now fully expensed. On April 26, 2016, the Company issued 1,667 options to an employee with an exercise price of $150.00 per share that will vest over three years at the anniversary date. The grant fair value was $213,750. During the year ended March 31, 2019 557 options were cancelled (March 31, 2018 – Nil) and $63,333 (March 31, 2018 - $71,250) was recognized as stock compensation expense. On August 8, 2016, the Company issued 5,000 options to an employee with an exercise price of $150.00 per share that will vest over three years at the anniversary date. The grant fair value was $652,068. During the year ended March 31, 2019, $48,301, (March 31, 2018 -$217,356) of stock compensation expense was recognized, 3,335 of the options were cancelled during the year ended March 31, 2019 as a result of this employee leaving. On February 6, 2017, the Company issued 2,667 options to an employee with an exercise price of $105.00 per share that will vest over three years at the anniversary date. The grant fair value was $245,200. During the year ended March 31, 2019, $81,733 (March 31, 2018 - $81,733) of stock compensation expense was recognized. On February 13, 2017, the Company issued 1,667 options to a consultant with an exercise price of $102.00 per share that will vest over one and one- half years, every six months. The grant fair value was $148,750. During the year ended March 31, 2019, $92,821, (March 31, 2018 -$49,583) of stock compensation expense was recognized and these options are now fully expensed. On August 3, 2017, 13,334 options at $31.50 per share to an executive officer, which vest equally over three years. In addition, this executive officer was also granted up to 10,000 additional performance options based on meeting sales targets for the years ended March 31, 2018 and 2019. The performance options will vest at market price if the performance objectives are met. This grant had a grant date fair value of $387,209 and $7,546 (March 31,2018 - $60,371) was recognized as share compensation expense for the year ended March 31, 2019. This officer left in April 2018 and all options were cancelled. On September 1, 2017, the Company granted 81,436 options at $24.15 per share equally to an executive officer and a consultant, who is now the Chairman of the Company. 27,148 options have vested and 50% of the remaining options vest on performance being met and 50% vest annually over 5 years for the CEO, for our Chairman the options vest over 5 years. The grant date fair value was $1,832,304 and $343,557 is the current expense for the year ended March 31, 2019. (March 31, 2018 - $381,730) On January 24, 2018, the Company granted 24,267 options at $23.25 per share to employees that vest equally on January 24, 2019, 2020 and 2021. 7,334 options were cancelled for the year ended March 31, 2019 (March 31, 2018 - $Nil). The grant fair value was $491,036 and $140,540 is the current stock compensation expense for the year ended March 31, 2019. (March 31, 2018 - $27,280) On April 30, 2018, the Company granted to an executive officer, 40,000 options with an exercise price of $9.74 that vest immediately with a 10-year expiry. These options were valued using the Black Scholes model and the following inputs were used: expected life 10 years, expected volatility 114% and a risk-free rate of 1.59%. As these options vested immediately as of the grant date and $363,714 of stock compensation expense was recorded for the year ended March 31, 2019. On June 11, 2018, the Company granted to a sales executive officer, 5,000 options with an exercise price of $6.93 per share that vest over three years from the anniversary of the grant and expire in 7 years. The options were valued using the Black Scholes model and the following inputs were used: expected life of 7 years, expected volatility of 114% and a risk-free rate of 1.59%. The grant fair value was $30,341 and $8,147 of stock compensation was recognized for year ended March 31, 2019. During the year ended March 31, 2019, the Company recorded $1,347,399 in share-based compensation related to the vesting of stock options (March 31, 2018 - $1,540,580). The following is a summary of stock options outstanding and exercisable as of March 31, 2019. These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions: Expected life Risk free Dividend Forfeiture Expected Grant date Grant date in years Rate Rate Rate volatility fair value February 17, 2015 2.89 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 2.25 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 2.22 1.59 % 0 % 0 % 114 % $ 118,957 November 24, 2015 3.65 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 3.71 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 5.11 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 4.07 1.59 % 0 % 0 % 114 % $ 213,750 February 6, 2017 4.86 1.59 % 0 % 0 % 114 % $ 245,200 February 13, 2017 4.88 1.59 % 0 % 0 % 114 % $ 148,750 September 1, 2017 8.43 1.59 % 0 % 0 % 114 % $ 1,832,304 January 24, 2018 5.82 1.59 % 0 % 0 % 114 % $ 491,036 April 30, 2018 9.06 1.59 % 0 % 0 % 114 % $ 363,714 June 11, 2018 6.20 1.59 % 0 % 0 % 114 % $ 30,341 Number of Options Weighted-Average Exercise Price Outstanding, March 31, 2018 170,675 75.00 Issued 45,000 9.42 Cancelled (32,679 ) 65.93 Outstanding, March 31, 2019 182,996 37.73 The following is a summary of stock options outstanding and exercisable as of March 31, 2019: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 150.000 1,112 26-Apr-23 1,112 105.000 2,667 06-Feb-24 1,778 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 485 30-Sep-24 485 157.500 1,876 30-Sep-24 1,876 142.500 24 02-Jun-25 24 157.500 90 02-Jun-25 90 37.500 221 30-Dec-25 221 142.500 164 30-Dec-25 164 24.150 81,436 01-Sep-27 27,148 23.250 16,934 24-Jan-25 5,867 9.735 40,000 19-Apr-28 40,000 6.930 5,000 10-Jun-25 - 182,996 111,752 The weighted-average remaining contractual term of the outstanding options is 7.20 years (March 31, 2018 – 7.46 years) and for the options that are exercisable the weighted average is 6.80 years (March 31, 2018 – 5.74 years).

WARRANTS

WARRANTS	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
WARRANTS
Shareholders Equity And Share Based Payments Stock Warrant [Text Block]	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Weighted Average Number of Exercise Price Warrants ($) Outstanding and exercisable, March 31, 2018 and June 30, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected warrant transaction 6,305 34.50 Issued in connection with anti-dilution provision connected warrant transaction 52,590 38.91 Expired (204,304) (51.85) Outstanding and exercisable, March 31, 2019 288,517 40.27 Expired (163,483) (38.91) Outstanding and exercisable June 30, 2019 125,034 20.07 During the quarter ended June 30, 2019, 163,483 warrants expired in accordance with their terms (June 30, 2018 – Nil) Common share purchase warrants The following is a summary of common share purchase warrants outstanding after the warrant offer to amend the additional warrant issue and the re-pricing of the warrants as of June 30, 2019. Exercise Number of Price ($) Warrants Expiry Date 90.00 15,658 March 31, 2023 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 125,034 The weighted-average remaining contractual term of the outstanding warrants was 3.07 years (June 30, 2018 - 2.01 years).	12. WARRANTS The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted -Average Exercise Price ($) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with conversion of loans and interest into common shares 106,709 9.375 Issued in connection with conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected with issuance of common shares 136,388 73.02 Issued in connection with anti-dilution provision connected with issuance of common shares 13,464 44.28 Outstanding and exercisable, March 31, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected warrant transaction 6,305 34.50 Issued in connection with anti-dilution provision connected warrant transaction 52,590 38.91 Expired (204,304 ) (51.85 ) Outstanding and exercisable, March 31, 2019 288,517 40.27 During the year ended March 31, 2019, 204,304 warrants expired in accordance with their terms (March 31, 2018 - Nil) During the year ended March 31, 2018, the Company consummated an offer to amend and exercise its then outstanding warrants, enabling the holders of the warrants to exercise such warrants for $37.50 per share. The Company received net proceeds of $1,125,038. The Company also converted loans and interest due. Due to an anti-dilution clause in the warrant agreements for such outstanding warrants during the year ended March 31, 2019, an additional 67,952 warrants were issued to the $73.02 per share warrant holders and 6,305 warrants to the $44.28 per share warrant holders. As a result of the anti-dilution clause, the exercise price of the warrants changed from $73.02 per share to $55.71 per share and from $44.28 per share to $34.50 per share as a result of this warrant transaction. The $34.49 per share warrants expired during the fiscal year ended March 31, 2019. Furthermore, due to an anti-dilution clause in the warrant agreements for such outstanding warrants during the year ended March 31, 2019, an additional 52,590 warrants were issued to the $55.71 per share warrant holders. As a result of the anti-dilution clause, the exercise price of the warrants changed from $55.71 per share to $38.91 per share as a result of this warrant transaction. During the fiscal year ended March 31, 2018, an additional 559 warrants were issued to the $120.00 per share warrant holders and 6,275 warrants were issued to the $210.00 per share warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $120.00 per share to $ 112.35 During the fiscal year ended March 31, 2018, due to an anti-dilution clause in the warrant agreements for such outstanding warrants an additional 13,464 warrants were issued to the $112.35 per share warrant holders and 136,388 warrants were issued to the $194.00 per share warrant holders. Furthermore, as a result of the anti-dilution clause, the exercise price of the warrants changed from $112.35 per share to $44.28 per share and from $194.00 per share to $73.02 per share as a result of loan and interest conversion transaction for shares that have been issued and shares that will be issued. The Company measured the effects of the above transactions, which triggered anti-dilution clause using the binomial option pricing model and recorded a loss for the year ended March 31, 2019 of $24,432 (March 31, 2018 -$74,086) against deficit. The Company issued 2,667 warrants exercisable at $37.50 per share for four years expiring June 27, 2020 to the firm who facilitated the warrant offer. The Company issued 15,658 warrants at $90.00 per share which expire in 5 years on March 31, 2023 and 106,709 warrants at $9.375 Common share purchase warrants The following is a summary of common share purchase warrants outstanding after the warrant offer to amend the additional warrant issue and the re-pricing of the warrants as of March 31, 2019. Exercise Price ($) Number of Warrants Expiry Date 90.00 15,658 March 31, 2023 38.91 84,562 April 21, 2019 38.91 39,922 May 27, 2019 38.91 38,998 June 30, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 288,517 The weighted-average remaining contractual term of the outstanding warrants was 1.51 years (March 31, 2018 – 2.27 years). The exercise price and number of underlying shares with respect to the remaining $38.91 per share warrants are expected to be further adjusted pursuant to the anti-dilution provisions therein, as a result of any further issuance of common shares.

INCOME TAXES

INCOME TAXES	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Income Tax Disclosure [Text Block]	13. INCOME TAXES Components of net loss before income taxes consists of the following: March 31 March 31 2019 2018 $ $ U.S. (8,849,294 ) (12,281,398 ) Canada (1,707,307 ) (2,344,392 ) (10,556,601 ) (14,625,790 ) Net loss for the year before recovery of income taxes (10,556,601 ) (14,625,790 ) Statutory rate 25.30 % 34.04 % Expected income tax (recovery) (2,670,579 ) (4,978,619 ) Tax rate changes and other basis adjustments (525,472 ) 1,748,278 Stock-based compensation 340,861 524,412 Difference in Foreign Tax Rates - - Accretion 890,797 184,414 Change in fair value (85,487 ) 659,458 (Gain) loss on mark to market re-evaluation (518,274 ) - Share premium - 425,497 Non-deductible expense 83,578 339,296 Net DTA acquired - - Change in valuation allowance 2,484,576 1,097,264 Recovery of income taxes - - The following deferred tax assets have not been recognized. Deferred tax reflects the tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities and consisted of the following: March 31, 2019 March 31, 2018 $ $ Equipment 70,650 70,350 Share issue costs - 510 SR&ED pool 844,001 690,320 Other 1,022,309 535,510 Non-capital losses – Canada 2,796,469 2,515,170 Net operating losses – U.S. 5,911,320 4,331,850 Valuation allowance (9,502,006 ) (7,017,430 ) 1,142,743 1,126,280 Intangibles and other (1,142,743 ) (1,126,280 ) - - The Company has non-capital losses in its Canadian subsidiary of approximately $10,552,713, which will expire between 2032 and 2039. The Company has net operating losses in the U.S. parent Company of $14,190,773, and net operating losses in the U.S. subsidiary of approximately $14,190,773, Income taxes are provided based on the liability method, which results in deferred tax assets and liabilities arising from temporary differences. Temporary differences are differences between the tax basis of assets and liabilities and their reported amounts in the consolidated financial statements that will result in taxable or deductible amounts in future years. The liability method requires the effect of tax rate changes on current and accumulated deferred taxes to be reflected in the period in which the rate change was enacted. The liability method also requires that deferred tax assets be reduced by a valuation allowance unless it is more likely than not that the assets will be realized. The Company recognizes the financial statement benefit of a tax position only after determining that the relevant tax authority would more likely than not sustain the position following an audit. For tax positions meeting the more-likely-than-not threshold, the amount recognized in the consolidated financial statements is the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement with the relevant tax authority. The Company recognizes interest accrued on uncertain tax positions as well as interest received from favorable tax settlements within interest expense. The Company recognizes penalties accrued on unrecognized tax benefits within general and administrative expenses. As of March 31, 2019, the Company had no uncertain tax positions. In many cases the Company’s uncertain tax positions are related to tax years that remain subject to examination by tax authorities. The following describes the open tax years, by major tax jurisdiction, as of March 31, 2019: United States – Federal 2015 – present United States – State 2015 – present Canada – Federal 2014 – present Canada – Provincial 2014 – present

RISK MANAGEMENT

RISK MANAGEMENT	12 Months Ended
	Mar. 31, 2019
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	14. RISK MANAGEMENT Concentrations of Credit Risk and Economic Dependence Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash on deposit with Canadian and US banks. The Company’s cash balances are maintained in various banks in Canada and the United States. Deposits held in banks in the United States are insured up to $ 250,000 Three of the Company’s customers accounted for 83.3%, 8.9% and 4.6% and 88.1%, 1.9% and 1.5%,

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
COMMITMENTS AND CONTINGENCIES
Commitments and Contingencies Disclosure [Text Block]	13. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 1,753 common shares were issued to two former lenders connected with a $241,185 loan received and repaid during fiscal 2013. The common shares were valued at $210,323 based on the value of the concurrent private placement and recorded in stock-based compensation on the consolidated statement of operations and comprehensive loss. As part of the consideration for the initial loan, the Company's then-CTO and COO had transferred 2,098 common shares to the lenders. For contributing the common shares to the lenders, the Company intends to reimburse the former CTO and COO 2,134 common shares. As at June 30, 2019 these shares have not yet been issued. (b) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form China Bionik Medical Rehabilitation Technology Ltd. (“China JV”), in which the Company will have a 25% interest and the JV Partner 75%. The China JV was formally established on receiving a business license on May 22, 2018. Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of the date of establishment, $435,000 12 months later and $725,000, 60 months after the date of establishment. The Company is required to license certain intellectual property to the China JV. The Company is applying the equity method of accounting to the joint venture. As of June 30, 2019, the Company has provided certain technical information to the Chinese JV in order to obtain Chinese regulatory approvals. (c) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, with a former director as a co- licenser, pursuant to which the Company pays the director and the co-licenser an aggregate royalty of 1% of sales based on patent #8,613,691. No sales have been made, as the technology under this patent has not been commercialized. (d) The Company has committed to upgrading two robots previously sold to a customer to the newest version when released. As part of this transaction, the customer will enter into an extended warranty agreement that will be approximately equal to the manufacturing value of robots.	15. COMMITMENTS AND CONTINGENCIES Contingencies From time to time, the Company may be involved in a variety of claims, suits, investigations and proceedings arising in the ordinary course of our business, collections claims, breach of contract claims, labor and employment claims, tax and other matters. Although claims, suits, investigations and proceedings are inherently uncertain and their results cannot be predicted with certainty, the Company believes that the resolution of current pending matters will not have a material adverse effect on its business, financial position, results of operations or cash flow. Regardless of the outcome, litigation can have an adverse impact on the Company because of legal costs, diversion of management resources and other factors. Commitments (a) On February 25, 2015, 1,753 241,185 210,323 2,098 2,134 (b) On May 17, 2017, the Company entered into a Co-operative Joint Venture Contract (the “JV Contract”) with Ginger Capital Investment Holding, Ltd. (the “JV Partner”) to form China Bionik Medical Rehabilitation Technology Ltd. (“China JV”), in which the Company will have a 25% 75 (c) In connection with the acquisition of IMT, the Company acquired a license agreement dated June 8, 2009, with a former director as a co- licenser, pursuant to which the Company pays the director and the co-licenser an aggregate royalty of 1 (d) The Company has committed to upgrading two robots previously sold to a customer to the newest version when released. As part of this transaction, the customer will enter into an extended warranty agreement that will be approximately equal to the manufacturing value of robots.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
SUBSEQUENT EVENTS
Subsequent Events [Text Block]	14. SUBSEQUENT EVENTS (a) Subsequent to June 30, 2019, the Company received an additional $4,560,000 from lenders under the terms of the convertible loans described in Note 8. (b) Subsequent to June 30, 2019, the Company issued up to 495,319 options to directors, employees and a consultant, under various vesting terms at a price up to $3.595.	16. SUBSEQUENT EVENTS (a) Subsequent to March 31, 2019, an exchangeable shareholder exchanged 6,083,900 40,560 (b) Subsequent to March 31, 2019, the Company’s Board granted 169,882 3.16 (c) Subsequent to March 31, 2019, an affiliate of the Company’s Chairman of the Board provided a $ 500,000 1 (d) Subsequent to March 31, 2019, an affiliate of one of the Company’s major shareholders who is also a director provided an aggregate amount of $ 500,000 9,000,000 1 9,000,000

SIGNIFICANT ACCOUNTING POLICI_2

SIGNIFICANT ACCOUNTING POLICIES (Policies)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
SIGNIFICANT ACCOUNTING POLICIES
Unaudited Condensed Consolidated Interim Financial Statements	Unaudited Condensed Consolidated Interim Financial Statements These unaudited condensed consolidated interim financial statements have been prepared on the same basis as the annual audited financial statements of the Company and should be read in conjunction with those annual audited financial statements filed on Form 10‑K for the year ended March 31, 2019. The interim disclosures generally do not repeat those in the annual statements. In the opinion of management, these unaudited condensed consolidated interim financial statements reflect all adjustments necessary to present fairly the Company’s financial position, results of operations and cash flows for the periods shown. The results of operations for such periods are not necessarily indicative of the results expected for a full year or for any future period. The changes in accounting policies in the Company’s unaudited condensed consolidated interim financial statements from the March 31, 2019 audited financial statements are described below.
New Accounting Pronouncements, Policy [Policy Text Block]	Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014‑09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014‑09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014‑09, as amended, is effective for the Company in the interim period ended June 30, 2019. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU‑2014‑1 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In November 2015, the FASB issued ASU No. 2015‑17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015‑17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU‑2015‑17 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016‑01 Financial Instruments - Overall (Subtopic 825‑10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825‑10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU 2016‑01 for the year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In February 2016, the FASB issued ASU 2016‑02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company has adopted ASU 2016‑02 and it did not have a material effect on the consolidated statement of financial position and consolidated statement of operations. In August 2016, the FASB issued ASU 2016‑15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016‑15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU 2016‑15 for the fiscal year ended March 31, 2019 and it did not have material effect on the consolidated financial position or on the consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted ASU 2017-09 during the year ended March 31, 2019 and it did not have a material effect on the consolidated financial statements and the consolidated results of operations.	Newly Adopted and Recently Issued Accounting Pronouncements Newly Adopted In May 2014, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) No. 2014-09, Revenue from Contracts with Customers (Topic 606). The updated standard will replace most existing revenue recognition guidance in U.S. GAAP. The new standard introduces a five-step process to be followed in determining the amount and timing of revenue recognition. It also provides guidance on accounting for costs incurred to obtain or fulfill contracts with customers and establishes disclosure requirements which are more extensive than those required under existing U.S. GAAP. The FASB has issued numerous amendments to ASU 2014-09 from August 2015 through January 2018, which provide supplemental and clarifying guidance, as well as amend the effective date of the new standard. ASU 2014-09, as amended, is effective for the Company in the interim period ended June 30, 2018. The standard permits the use of either the retrospective or modified retrospective (cumulative effect) transition method. The Company adopted the new standard using the modified retrospective transition method. The Company has adopted ASU-2014-1 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In November 2015, the FASB issued ASU No. 2015-17, “Balance Sheet Classification of Deferred Taxes,” which require that deferred tax liabilities and assets be classified on our Consolidated Balance Sheets as noncurrent based on an analysis of each taxpaying component within a jurisdiction. ASU No. 2015-17 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU-2015-17 for the fiscal year ended March 31, 2019 and it did not have a material effect on the consolidated financial position or the consolidated results of operations. In January 2016, the FASB issued ASU No. 2016-01 Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities. The updates make several modifications to Subtopic 825-10, including the elimination of the available-for-sale classification of equity investments, and it requires equity investments with readily determinable fair values to be measured at fair value with changes in fair value recognized in operations. The update is effective for fiscal years beginning after December 2017. The Company has adopted ASU 2016-01 for the year ended March 31, 2019 and it did not have a material effect on the consolidated financial position and the consolidated results of operations. In August 2016, the FASB issued ASU 2016-15, “Statement of Cash Flows: Classification of Certain Cash Receipts and Cash Payments”. This ASU provides eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for the fiscal year commencing after December 15, 2017. The Company has adopted ASU 2016-15 for the fiscal year ended March 31, 2019 and it did not have material effect on the consolidated financial position or on the consolidated statement of cash flows. In May 2017, the FASB issued ASU No. 2017-09, Compensation - Stock Compensation (Topic 718): Scope of Modification Accounting (ASU 2017-09). The FASB issued the update to provide clarity and reduce the cost and complexity when applying the guidance in Topic 718. The amendments in this update provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in Topic 718. The Company adopted ASU 2017-09 during the year ended March 31, 2019 and it did not have a material effect on the consolidated financial statements and the consolidated results of operations.
Recently Adopted Accounting Pronouncements [Policy Text Block]	Recently Issued In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated financial position or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2017-04 will have on the consolidated statement of financial position and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2016-13 will have on the consolidated statement of financial position and consolidated statement of operations.	Recently Issued In January 2017, the FASB issued ASU 2017-01, “Business Combinations: Clarifying the definition of a Business” which amends the current definition of a business. Under ASU 2017-01, to be considered a business, an acquisition would have to include an input and a substantive process that together significantly contributes to the ability to create outputs. ASU 2017-01 further states that when substantially all of the fair value of gross assets acquitted is concentrated in a single asset (or a group of similar assets), the assets acquired would not represent a business. The new guidance also narrows the definition of the term “outputs” to be consistent with how it is described in Topic 606, Revenue from Contracts with Customers. The changes to the definition of a business will likely result in more acquisitions being accounted for as asset acquisitions. ASU 2017-01 is effective for acquisitions commencing on or after June 30, 2019, with early adoption permitted. Adoption of this guidance will be applied prospectively on or after the effective date and the Company does not expect this policy will have a material effect on the consolidated financial position or consolidated statement of cash flows. In January 2017, the FASB issued ASU 2017-04, “Intangibles – Goodwill and Other” ASU 2017-04 simplifies the accounting for goodwill impairment by eliminating Step 2 of the current goodwill impairment test, which required a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which the reporting unit’s carrying value exceeds its fair value, limited to the carrying value of the goodwill. ASU 2017-04 is effective for financial statements issued for fiscal years, and interim periods beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2017-04 will have on the consolidated statement of financial position and consolidated statement of operations. In June 2016, the FASB issued ASU 2016-13 Financial Instruments – Credit Losses (Topic 326): Measurement of Credit Losses of Financial Instruments, which introduces an expected credit loss methodology for the impairment of financial assets measured at amortized cost basis. The methodology replaces the probable, incurred loss model for those assets. The update if effective for fiscal years beginning after December 15, 2019. The Company is still assessing the impact that the adoption of ASU 2016-13 will have on the consolidated statement of financial position and consolidated statement of operations. In February 2016, the FASB issued ASU 2016-02, Leases. This update requires organizations that lease assets to recognize on the balance sheet the assets and liabilities for the rights and obligations created by those leases. The new guidance will also require additional disclosure about the amount, timing and uncertainty of cash flows arising from leases. The provisions of this update are effective for annual and interim periods beginning after December 15, 2018. The Company is still assessing the impact that the adoption of ASU 2016-02 will have on the consolidated statement of financial position and consolidated statement of operations.
Inventory, Policy [Policy Text Block]		Inventory Inventory is stated at the lower of cost or net realizable value. Cost is recorded at actual cost, on the first-in first-out basis. The Company only has finished goods inventory recoded based on actual cost from outsourced manufacturing partner.
Revenue Recognition, Policy [Policy Text Block]		Revenue Recognition The Company has adopted ASU-2014-9 with initial application date of April 1, 2018. The Company adopted the new standard using the modified retrospective transition method. The updated accounting policies and the impact on the consolidated audited financial statements and additional disclosures are as follows: The Company determines revenue through the following steps: a) identification of the contract with the customer; b) identification of the performance obligations in the contract; c) determination of the transaction price; d) allocation of the transaction price for the performance obligations in the contract; and e) recognition of revenue when or as the Company satisfies a performance obligation. Revenue is recognized when control of a product is transferred to a customer. Revenue is measured based on the consideration specified in the contract with the customer, net of returns and discounts. Accruals for sales returns are calculated based on the best estimate of the amount of product that will ultimately be returned by customers, reflecting historical experience and the magnitude of non-conforming inventory claims made by customer that have either been approved or are pending review. Contract liabilities are recorded when cash payments are received or due in advance of the Company’s performance. The Company defers revenue from extended warranty sales and recognizes them over the period of extended warranty and from training services when the training is provided. In the comparative period, the revenue was measured at the fair value of the consideration received or receivable, net of returns and discounts and was recognized when the risks and rewards of ownership has transferred to the customer. No revenue was recognized if there were significant uncertainties regarding recovery of the consideration due, the costs incurred or to be incurred could not be measured reliably, or there was continuing management involvement with the goods.
Receivables, Trade and Other Accounts Receivable, Allowance for Doubtful Accounts, Policy [Policy Text Block]		Allowance for doubtful accounts The Company extends unsecured credit to its customers in the ordinary course of business but mitigates the associated credit risk by supplying products to customers with pre-approved capital expenditure budgets or rental credit, and by actively pursuing past due accounts. An allowance for doubtful accounts is estimated and recorded based on management’s assessment of the credit history with the customer and the current relationships with them. On this basis management has determined that an allowance for doubtful accounts of $Nil and $ 19,694
Standard Product Warranty, Policy [Policy Text Block]	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the condensed consolidated interim balance sheets and amounted to $168,000 at June 30, 2019 (March 31, 2019 - $143,500). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $26,911 of expenses related to warranty expenses and recorded this expense in cost of goods sold for the three-month period ended June 30, 2019 (June 30, 2018 – $10,108).	Warranty Reserve and Deferred Warranty Revenue The Company provides a one-year warranty as part of its normal sales offering. When products are sold, the Company provides warranty reserves, which, based on the historical experience of the Company are sufficient to cover warranty claims. Accrued warranty reserves are included in accrued liabilities on the consolidated balance sheets and amounted to $143,500 at March 31, 2019 (March 31, 2018 - $64,957). The Company also sells extended warranties for additional periods beyond the standard warranty. Extended warranty revenue is deferred and recognized as revenue over the extended warranty period. The Company recognized $84,038 of expenses related to warranty expenses and recorded this expense in cost of goods sold for the year ended March 31, 2019 (March 31, 2018 - $Nil).
Foreign Currency Transactions and Translations Policy [Policy Text Block]		Foreign Currency Translation The functional and presentation currency of the Company and its wholly owned subsidiaries is the U.S. dollar. Transactions denominated in a currency other than the functional currency are recorded on the initial recognition at the exchange rate at the date of the transaction. After initial recognition monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange differences are recognized in profit and loss. Non- monetary assets and liabilities measured at cost are translated at the exchange rate at the date of the transaction.
Property, Plant and Equipment, Policy [Policy Text Block]		Equipment Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows: Computer and Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum Assets under capital lease Life of lease (60 months)
Use of Estimates, Policy [Policy Text Block]		Use of Estimates The preparation of the consolidated financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting periods. The estimates based on management’s best knowledge of current events and actions of the Company may undertake in the future. Significant areas requiring the use of estimates relate to the valuation of inventory, the useful life of equipment and intangible assets, impairment of goodwill and intangible assets, share based compensation, warranty accruals, accretion, fair value adjustment and fair value determination of warrants. Actual results could differ from these estimates.
Fair Value of Financial Instruments, Policy [Policy Text Block]		Fair Value of Financial Instruments ASC Topic 820 defines fair value, establishes a framework for measuring fair value, and expands disclosures about fair value measurements. Included in the ASC Topic 820 framework is a three level valuation inputs hierarchy with Level 1 being inputs and transactions that can be effectively fully observed by market participants spanning to Level 3 where estimates are unobservable by market participants outside of the Company and must be estimated using assumptions developed by the Company. The Company discloses the lowest level input significant to each category of asset or liability valued within the scope of ASC Topic 820 and the valuation method as exchange, income or use. The Company uses inputs, which are as observable as possible, and the methods most applicable to the specific situation of each company or valued item. The carrying amounts reported in the balance sheets for cash and cash equivalents, accounts receivable, other receivables, accounts payable, accrued liabilities, due from related parties, demand loans, convertible loans and promissory note payable approximate fair value because of the short period of time between the origination of such instruments, their expected realization and their current market rates of interest. Per ASC Topic 820 framework these are considered Level 2 inputs where inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices in active markets for similar assets or liabilities, quoted prices for identical or similar assets or liabilities in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company’s policy is to recognize transfers into and out of Level 3 as of the date of the event or change in the circumstances that caused the transfer. There were no such transfers during the year.
Segment Reporting, Policy [Policy Text Block]		Segment Reporting ASC 280-10, “Disclosures about Segments of an Enterprise and Related Information”, establishes standards for the way that public business enterprises report information about operating segments in the Company’s consolidated financial statements. Operating segment are components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker in deciding how to allocate resources and in assessing performance. Approximately 99 148,618 120,910 43,910 39,051
Cash and Cash Equivalents, Policy [Policy Text Block]		Cash and Cash Equivalents Cash and cash equivalents include highly liquid investments with original terms to maturity of 90 days or less at the date of purchase. For all periods presented cash and cash equivalents consisted entirely of cash on deposit with Canadian and US banks.
Research and Development Expense, Policy [Policy Text Block]		Research and Development The Company is engaged in research and development work. Research and development costs are charged to operating expenses of the Company as incurred.
Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]		Share based compensation At grant date share-based compensation is valued using the Black-Scholes option pricing model based on key assumptions determined by the Company. The value is recognized based on the straight- line method during the vesting period or based on the fulfillment of predetermined milestones in case of performance-based vesting.
Income Tax, Policy [Policy Text Block]		Income Taxes Income taxes are computed in accordance with the provisions of ASC Topic 740, which requires, among other things, a liability approach to calculating deferred income taxes. The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been recognized in its consolidated financial statements or tax returns. Under this method, deferred tax liabilities and assets are determined based on the difference between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect in the years in which the differences are expected to reverse. The Company is required to make certain estimates and judgments about the application of tax law, the expected resolution of uncertain tax positions and other matters. In the event that uncertain tax positions are resolved for amounts different than the Company’s estimates, or the related statutes of limitations expire without the assessment of additional income taxes, the Company will be required to adjust the amounts of related assets and liabilities in the period in which such events occur. Such adjustment may have a material impact on the Company’s income tax provision and results of operations.
Earnings Per Share, Policy [Policy Text Block]		Basic and Diluted Loss Per Share Basic and diluted loss per share has been determined by dividing the net loss available to shareholders for the applicable period by the basic and diluted weighted average number of shares outstanding, respectively. The diluted weighted average number of shares outstanding is calculated as if all dilutive options had been exercised or vested at the later of the beginning of the reporting period or date of grant, using the treasury stock method. Loss per common share is computed by dividing the net loss by the weighted average number of shares of common shares outstanding during the period. Common share equivalents, options and warrants were excluded from the computation of diluted loss per share because their effect was anti-dilutive.
Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]		Impairment of Long-Lived Assets The Company follows the ASC Topic 360, which requires that long-lived assets be reviewed for impairment whenever events or changes in circumstances indicate that the assets’ carrying amounts may not be recoverable. In performing the review for recoverability, if future undiscounted cash flows (excluding interest charges) from the use and ultimate disposition of the assets are less than their carrying values, an impairment loss represented by the difference between its fair value and carrying value, is recognized. When properties are classified as held for sale, they are recorded at the lower of the carrying amount or the expected sales price less costs to sell.
Goodwill and Intangible Assets, Policy [Policy Text Block]		Goodwill and Indefinite Lived Intangible Assets The Company records goodwill when the purchase price of an acquisition exceeds the fair value of the net tangible and identified intangible assets acquired. Goodwill and indefinite lived intangible assets, consisting of the trademarks acquired (Note 4), are assessed for impairment annually, or more frequently if indicators of potential impairment exist, which includes evaluating qualitative and quantitative factors to assess the likelihood of an impairment of goodwill or indefinite lived intangible assets. The qualitative factors used in the analysis include microeconomic conditions, industry and market conditions, cost factors, overall financial performance and other relevant entity specific events. The Company performs impairment tests using a fair value approach when necessary. None of the Company’s goodwill or indefinite lived intangibles was impaired as of March 31, 2019. Accordingly, no impairment loss has been recognized in the year ended March 31, 2019.

SIGNIFICANT ACCOUNTING POLICI_3

SIGNIFICANT ACCOUNTING POLICIES (Tables)	12 Months Ended
	Mar. 31, 2019
SIGNIFICANT ACCOUNTING POLICIES
Schedule of Property Plan Equipment Method [Table Text Block]	Equipment is recorded at cost. Depreciation is computed using the declining balance method, over the estimated useful lives of these assets. The costs of improvements that extend the life of equipment are capitalized. All ordinary repair and maintenance costs are expensed as incurred. Equipment is depreciated as follows: Computer and Electronics 50% per annum Furniture and Fixtures 20% per annum Demonstration Equipment 50% per annum Manufacturing Equipment 20% per annum Tools and Parts 20% per annum Assets under capital lease Life of lease (60 months)

TECHNOLOGY AND OTHER ASSETS (Ta

TECHNOLOGY AND OTHER ASSETS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
TECHNOLOGY AND OTHER ASSETS
Business Acquisition, Pro Forma Information [Table Text Block]	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the three months ended June 30, 2019, and the year ended March 31, 2019: Amortization Expenses Value at Expenses Value at period (years) Value acquired March 31, 2019 March 31, 2019 June 30, 2019 June 30, 2019 Intangible assets acquired $ $ $ $ $ Patents and exclusive License Agreement 9.74 1,306,031 134,126 911,440 33,522 877,918 Trademark Indefinite 2,505,907 — 2,505,907 — 2,505,907 Customer relationships 10 1,431,680 143,206 1,010,375 35,792 974,583 Non compete agreement 2 61,366 1,739 — — — Assembled workforce 1 275,720 — — — — 5,580,704 278,997 4,427,722 69,314 4,358,408	The schedule below reflects the intangible assets acquired in the IMT acquisition and the assets amortization period and expense for the year ended March 31, 2019: Amortization period (years) Value acquired Expense March 31, 2018 Value at March 31, 2018 Expenses March 31, 2019 Value at March 31, 2019 Intangible assets acquired $ $ $ $ $ Patents and exclusive Licence Agreement 9.74 1,306,031 134,126 1,045,530 134,090 911,440 Trademark Indefinite 2,505,907 - 2,505,907 - 2,505,907 Customer relationships 10 1,431,680 143,206 1,153,543 143,168 1,010,375 Non compete agreement 2 61,366 30,709 1,739 1,739 - Assembled workforce 1 275,720 15,864 - - - 5,580,704 323,905 4,706,719 278,997 4,427,722

PREPAID EXPENSES AND OTHER RE_2

PREPAID EXPENSES AND OTHER RECEIVABLES (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
PREPAID EXPENSES AND OTHER RECEIVABLES
Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]	June 30, March 31, 2019 2019 $ $ Prepaid expenses and other receivables 75,780 92,170 Prepaid inventory 939,593 1,144,392 Prepaid insurance 160,787 66,320 Sales taxes receivable (i) 18,567 52,150 1,194,727 1,355,032 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.	March 31, 2019 March 31, 2018 $ $ Prepaid expenses and other receivables 92,170 86,957 Prepaid inventory 1,144,392 301,104 Prepaid insurance 66,320 36,497 Sales taxes receivable (i) 52,150 9,097 1,355,032 433,655 i) Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Tables)

INVENTORIES (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
INVENTORIES
Schedule of Inventory, Current [Table Text Block]	June 30, March 31, 2019 2019 Finished Goods 582,058 405,682	March 31, 2019 March 31, 2018 $ $ Raw Materials - 237,443 Finished Goods 405,682 - 405,682 237,443

EQUIPMENT (Tables)

EQUIPMENT (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
EQUIPMENT
Property, Plant and Equipment [Table Text Block]	Equipment consisted of the following as at June 30, 2019 and March 31, 2019: June 30, 2019 March 31, 2019 Accumulated Accumulated Cost Depreciation Net Cost Depreciation Net $ $ $ $ $ $ Computers and electronics 286,855 248,357 38,498 286,855 243,346 43,509 Furniture and fixtures 36,795 29,999 6,796 36,795 29,648 7,147 Demonstration equipment 314,417 164,363 150,054 271,615 147,257 124,358 Manufacturing equipment 88,742 86,353 2,389 88,742 86,230 2,512 Tools and parts 11,422 7,007 4,415 11,422 6,779 4,643 Assets under capital lease 23,019 13,811 9,208 23,019 12,660 10,359 761,250 549,890 211,360 718,448 525,920 192,528	Equipment consisted of the following as at March 31, 2019 and March 31, 2018: March 31, 2019 March 31, 2018 Cost Accumulated Depreciation Net Cost Accumulated Depreciation Net $ $ $ $ $ $ Computers and electronics 286,855 243,346 43,509 256,505 223,750 32,755 Furniture and fixtures 36,795 29,648 7,147 36,795 28,051 8,744 Demonstration equipment 271,615 147,257 124,358 200,186 105,441 94,745 Manufacturing equipment 88,742 86,230 2,512 88,742 85,668 3,074 Tools and parts 11,422 6,779 4,643 11,422 5,741 5,681 Assets under capital lease 23,019 12,660 10,359 23,019 8,057 14,962 718,448 525,920 192,528 616,669 456,708 159,961

NOTES PAYABLE (Tables)

NOTES PAYABLE (Tables)	12 Months Ended
	Mar. 31, 2019
Convertible Debt [Table Text Block]	Balance, March 31, 2016 $ - Additional principal investment 2,000,000 Accrued Interest 17,488 Balance, March 31, 2017 2,017,488 Additional principal investment 2,999,975 Fair value of warrants (548,178 ) Accretion expense 548,178 Accrued Interest 1,037,067 Conversion of principal and interest (6,054,530 ) Balance, March 31, 2018 and March 31, 2019 $ -
Schedule of Conversion of Notes Payable [Table Text Block]	March 31, 2018 Principal Interest Premium Total Conversion Amount Beneficial Conversion Feature Number of Shares Converted Convertible Notes Payable (December 2016 to December 2017) $ 4,999,975 $ 1,054,555 $ 1,249,994 $ 7,304,523 $ 762,301 779,461 Chinese Convertible Loan $ 500,000 $ 33,556 - $ 533,556 $ 76,230 62,629 Convertible Notes Payable (December 2017 to March 2018) $ 3,611,400 $ 201,928 - $ 3,813,328 $ 550,598 406,918 Total $ 9,111,375 $ 1,290,039 $ 1,249,994 $ 11,651,407 $ 1,389,129 1,249,008
Schedule of Convertible Debt Fair Value [Table Text Block]	The tables below reflect the fair value and anti-dilution features of the convertible loans, which resulted in accretion expense related to the loans: At issuance At July 20, 2018 Principal Conversion feature fair value Ending Conversion Anti-dilution Fair value of debt Accretion expense Interest balance before conversion Convertible promissory note $ 4,708,306 $ 406,744 $ 1,697,674 $ 2,603,888 $ 2,104,418 $ 24,547 $ 4,732,853 Conversion Anti-dilution Total Conversion feature fair value At Issuance $ 406,744 $ 1,697,674 $ 2,104,418 Fair value adjustment $ (406,744 ) $ 68,821 $ (337,923 ) Balance allocated to equity on conversion $ - $ (1,766,495 ) $ (1,766,495 ) Ending balance at March 31, 2019 $ - $ - $ -
Schedule of Convertible Debt Beneficial Conversion Feature [Table Text Block]	At issuance At March 28, 2019 Principal Accretion expense Interest Ending Balance Convertible promissory note $ 4,650,000 $ 1,162,500 $ 198,117 $ 6,010,617
Convertible Debt [Member]
Schedule of Short-term Debt [Table Text Block]	Balance, March 31, 2017 $ - Additional principal investment 500,000 Accrued Interest 33,556 Conversion of principal and interest (533,556 ) Balance, March 31, 2018 and March 31, 2019 $ - $3,611,400 was received from these investors during the twelve months ended March 31, 2018 and $201,928 of interest was accrued and expensed on these convertible loans for the twelve months ended March 31, 2018. Balance, March 31, 2017 - Additional principal investment 3,611,400 Accrued Interest 201,928 Conversion of principal and interest (3,813,328 ) Balance, March 31, 2018 and March 31, 2019 $ -
Demand Notes payable [Member]
Schedule of Accounts Payable and Accrued Liabilities [Table Text Block]	Balance March 31, 2017 330,600 Accrued interest 8,497 Repayment (287,618 ) Balance, March 31, 2018 $ 51,479 Accrued interest 1,496 Repayment (52,975 ) Balance, March 31, 2019 $ -

SHARE CAPITAL (Tables)

SHARE CAPITAL (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
SHARE CAPITAL
Schedule of Stockholders Equity [Table Text Block]	June 30, 2019 March 31, 2019 Number of Number of shares $ shares $ Exchangeable Shares Balance beginning of year 196,799 197 295,146 295 Converted into common shares (a) (40,560) (41) (98,347) (98) Balance at end of year 156,239 156 196,799 197 Common Shares Balance at beginning of the year 3,661,838 3,661 1,368,856 1,369 Shares issued to exchangeable shareholders (a) 40,560 41 98,347 98 Shares issued on conversion of loans — — 2,194,133 2,194 Share consolidation rounding adjustment — — 502 — Balance at end of the year 3,702,398 3,661 3,661,838 3,661 TOTAL SHARES 3,858,637 3,858 3,858,637 3,858 (a) During the quarter ended June 30, 2019, 40,560 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2019 – 98,347 shares) (b) On October 29, 2018, the Company completed a one-for-one hundred and fifty (1:150) reverse stock consolidation that has been reflected in all shares and per share amounts, warrants and options.	March 31, 2019 March 31, 2018 Number of shares $ Number of shares $ Exchangeable Shares Balance beginning of year 295,146 295 319,396 319 Converted into common shares (d) (98,347 ) (98 ) (24,250 ) (24 ) Balance at end of year 196,799 197 295,146 295 Common Shares Balance at beginning of the year 1,368,856 1,369 325,901 326 Shares issued to exchangeable shareholders (d) 98,347 98 24,250 24 Shares issued on conversion of loans (b) (c) 2,194,133 2,194 985,370 986 Warrants exercised (a) - - 33,335 33 Share consolidation rounding adjustment 502 - - - Balance at end of the year 3,661,838 3,661 1,368,856 1,369 TOTAL SHARES 3,858,637 3,858 1,664,002 1,664 (a) During the year ended March 31, 2018, the Company consummated an offer to amend and exercise to its warrant holders, enabling them to exercise their outstanding warrants for $37.50 per share, and as a result, 33,335 common shares were issued for net proceeds of $1,125,038 (Note 12). (b) During the year ended March 31, 2018, the Company converted $9,058,708 of notes payable and interest into 985,370 common shares. Under the terms of this conversion the remaining $1,342,705 of principal and interest was required to be converted into 263,639 common shares, but they were unable to be issued as a result of the Company not having enough authorized shares. The $2,470,622 value of these shares at March 31, 2018 has been classified as a liability until the common shares can be issued. In addition, there was a $376,674 loss recorded in the year connected to the difference of the $2,847,296 market value of the shares at March 31, 2018 and the value of these shares which resulted on the conversion of notes payable, the exercise price of which was based on a 30-day VWAP. The fair value of these shares ($2,847,296), outstanding warrants ($1,394,164) and options ($1,451,393) at March 31, 2018 represented the $5,692,853 liability on the Company’s balance sheet. (c) During the year ended March 31, 2019, after the increase of the number of authorized shares to 500,000,000, the company issued the outstanding 263,639 common shares related to the March 31, 2018 promissory note conversion. In addition, there was a $2,048,697 gain recorded in the year connected to the difference of the market value of the shares, outstanding options and warrants at March 31, 2018 and their value at June 12, 2018, the time of the authorized share increase and share issuance. On July 20, 2018 the Company converted $4,708,306 of notes payable and interest into 683,395 common shares and on March 28, 2019 the Company converted $4,848,117 of notes payable and interest into 1,247,099 common shares. (Note 8) (d) During the year ended March 31, 2019, 98,347 exchangeable shares were exchanged for common shares on a 1 for 1 basis in accordance with their terms. (March 31, 2018 – 24,250 shares) (e) On October 29, 2018, the Company completed a one-for-one hundred and fifty to one (1:150) reverse stock consolidation that has been reflected in all shares and per share amounts, warrants and options.

STOCK OPTIONS (Tables)

STOCK OPTIONS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
STOCK OPTIONS
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]		These options at their respective grant dates were valued using the Black-Scholes option pricing model with the following key assumptions: Expected life Risk free Dividend Forfeiture Expected Grant date Grant date in years Rate Rate Rate volatility fair value February 17, 2015 2.89 1.59 % 0 % 0 % 114 % $ 136,613 July 1, 2014 2.25 1.59 % 0 % 0 % 114 % $ 1,259,487 June 20, 2014 2.22 1.59 % 0 % 0 % 114 % $ 118,957 November 24, 2015 3.65 1.59 % 0 % 0 % 114 % $ 694,384 December 14, 2015 3.71 1.59 % 0 % 0 % 114 % $ 1,260,437 April 21, 2016 5.11 1.59 % 0 % 0 % 114 % $ 2,582,890 April 26, 2016 4.07 1.59 % 0 % 0 % 114 % $ 213,750 February 6, 2017 4.86 1.59 % 0 % 0 % 114 % $ 245,200 February 13, 2017 4.88 1.59 % 0 % 0 % 114 % $ 148,750 September 1, 2017 8.43 1.59 % 0 % 0 % 114 % $ 1,832,304 January 24, 2018 5.82 1.59 % 0 % 0 % 114 % $ 491,036 April 30, 2018 9.06 1.59 % 0 % 0 % 114 % $ 363,714 June 11, 2018 6.20 1.59 % 0 % 0 % 114 % $ 30,341
Share-based Compensation, Stock Options, Activity [Table Text Block]		Number of Options Weighted-Average Exercise Price Outstanding, March 31, 2018 170,675 75.00 Issued 45,000 9.42 Cancelled (32,679 ) 65.93 Outstanding, March 31, 2019 182,996 37.73
Share-based Compensation, Performance Shares Award Outstanding Activity [Table Text Block]	The following is a summary of stock options outstanding and exercisable as of June 30, 2019: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 105.000 2,667 06-Feb-24 1,778 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 485 30-Sep-24 485 157.500 1,876 30-Sep-24 1,876 24.150 81,436 01-Sep-27 27,148 23.250 15,656 24-Jan-25 5,867 9.735 40,000 19-Apr-28 40,000 3.16 169,882 31-May-26 56,627 344,989 166,768	The following is a summary of stock options outstanding and exercisable as of March 31, 2019: Exercise Price ($) Number of Options Expiry Date Exercisable Options 34.500 630 20-Jun-21 630 34.500 13,212 01-Jul-21 13,212 34.500 944 17-Feb-22 944 183.000 2,667 24-Nov-22 2,667 150.000 11,400 14-Dec-22 11,400 142.500 359 28-Mar-23 359 157.500 1,387 28-Mar-23 1,387 150.000 1,112 26-Apr-23 1,112 105.000 2,667 06-Feb-24 1,778 102.000 1,667 13-Feb-24 1,667 142.500 106 03-Mar-24 106 157.500 408 03-Mar-24 408 142.500 43 14-Mar-24 43 157.500 164 14-Mar-24 164 142.500 485 30-Sep-24 485 157.500 1,876 30-Sep-24 1,876 142.500 24 02-Jun-25 24 157.500 90 02-Jun-25 90 37.500 221 30-Dec-25 221 142.500 164 30-Dec-25 164 24.150 81,436 01-Sep-27 27,148 23.250 16,934 24-Jan-25 5,867 9.735 40,000 19-Apr-28 40,000 6.930 5,000 10-Jun-25 - 182,996 111,752

WARRANTS (Tables)

WARRANTS (Tables)	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
WARRANTS
Schedule Of Share Based Compensation Stock Purchase Warrants Activity [Table Text Block]	The following is a continuity schedule of the Company’s common share purchase warrants: Weighted Average Number of Exercise Price Warrants ($) Outstanding and exercisable, March 31, 2018 and June 30, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected warrant transaction 6,305 34.50 Issued in connection with anti-dilution provision connected warrant transaction 52,590 38.91 Expired (204,304) (51.85) Outstanding and exercisable, March 31, 2019 288,517 40.27 Expired (163,483) (38.91) Outstanding and exercisable June 30, 2019 125,034 20.07	The following is a continuity schedule of the Company’s common share purchase warrants: Number of Warrants Weighted -Average Exercise Price ($) Outstanding and exercisable, March 31, 2017 117,589 202.50 Exercised (33,335 ) (37.50 ) Issued in connection with anti-dilution provision connected warrant transaction 559 112.35 Issued in connection with anti-dilution provision connected warrant transaction 6,275 194.00 Issued in connection to the warrant transaction to the broker 2,667 37.50 Issued in connection with conversion of loans and interest into common shares 106,709 9.375 Issued in connection with conversion of loans and interest into common shares 15,658 90.00 Issued in connection with anti-dilution provision connected with issuance of common shares 136,388 73.02 Issued in connection with anti-dilution provision connected with issuance of common shares 13,464 44.28 Outstanding and exercisable, March 31, 2018 365,974 53.19 Issued in connection with anti-dilution provision connected warrant transaction 67,952 55.71 Issued in connection with anti-dilution provision connected warrant transaction 6,305 34.50 Issued in connection with anti-dilution provision connected warrant transaction 52,590 38.91 Expired (204,304 ) (51.85 ) Outstanding and exercisable, March 31, 2019 288,517 40.27
Schedule of Common Share Purchase Warrants Outstanding [Table Text Block]	The following is a summary of common share purchase warrants outstanding after the warrant offer to amend the additional warrant issue and the re-pricing of the warrants as of June 30, 2019. Exercise Number of Price ($) Warrants Expiry Date 90.00 15,658 March 31, 2023 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 125,034	The following is a summary of common share purchase warrants outstanding after the warrant offer to amend the additional warrant issue and the re-pricing of the warrants as of March 31, 2019. Exercise Price ($) Number of Warrants Expiry Date 90.00 15,658 March 31, 2023 38.91 84,562 April 21, 2019 38.91 39,922 May 27, 2019 38.91 38,998 June 30, 2019 37.50 2,667 June 27, 2020 9.375 64,025 August 14, 2022 9.375 42,684 March 31, 2022 288,517

INCOME TAXES (Tables)

INCOME TAXES (Tables)	12 Months Ended
	Mar. 31, 2019
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	Components of net loss before income taxes consists of the following: March 31 March 31 2019 2018 $ $ U.S. (8,849,294 ) (12,281,398 ) Canada (1,707,307 ) (2,344,392 ) (10,556,601 ) (14,625,790 ) Net loss for the year before recovery of income taxes (10,556,601 ) (14,625,790 ) Statutory rate 25.30 % 34.04 % Expected income tax (recovery) (2,670,579 ) (4,978,619 ) Tax rate changes and other basis adjustments (525,472 ) 1,748,278 Stock-based compensation 340,861 524,412 Difference in Foreign Tax Rates - - Accretion 890,797 184,414 Change in fair value (85,487 ) 659,458 (Gain) loss on mark to market re-evaluation (518,274 ) - Share premium - 425,497 Non-deductible expense 83,578 339,296 Net DTA acquired - - Change in valuation allowance 2,484,576 1,097,264 Recovery of income taxes - -
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	The following deferred tax assets have not been recognized. Deferred tax reflects the tax effects of temporary differences that gave rise to significant portions of deferred tax assets and liabilities and consisted of the following: March 31, 2019 March 31, 2018 $ $ Equipment 70,650 70,350 Share issue costs - 510 SR&ED pool 844,001 690,320 Other 1,022,309 535,510 Non-capital losses – Canada 2,796,469 2,515,170 Net operating losses – U.S. 5,911,320 4,331,850 Valuation allowance (9,502,006 ) (7,017,430 ) 1,142,743 1,126,280 Intangibles and other (1,142,743 ) (1,126,280 ) - -
Summary of Income Tax Examinations [Table Text Block]	In many cases the Company’s uncertain tax positions are related to tax years that remain subject to examination by tax authorities. The following describes the open tax years, by major tax jurisdiction, as of March 31, 2019: United States – Federal 2015 – present United States – State 2015 – present Canada – Federal 2014 – present Canada – Provincial 2014 – present

NATURE OF OPERATIONS AND GOIN_2

NATURE OF OPERATIONS AND GOING CONCERN (Details Textual)	Oct. 29, 2018	Feb. 26, 2015shares	Feb. 25, 2015shares	Feb. 13, 2015	Oct. 29, 2018	Apr. 21, 2016shares	Feb. 13, 2015	Jun. 30, 2019USD ($)shares	Jun. 30, 2018USD ($)	Mar. 31, 2019USD ($)shares	Mar. 31, 2018USD ($)shares	Jun. 12, 2018shares	Nov. 06, 2017shares	Mar. 31, 2017shares	Dec. 31, 2014shares
Stock Issued During Period, Shares, New Issues			1,753
Working Capital Surplus (Deficit) | $								$ (802,997)		$ 479,408	$ (6,711,941)
Comprehensive Income (Loss), Net of Tax | $								$ (2,120,644)	$ (760,698)	$ (10,556,601)	$ (14,625,790)
Common Stock, Shares Authorized								500,000,000		500,000,000	250,000,000	500,000,000	250,000,000	150,000,000	200,000,000
Reverse stock split ratio	0.0067			0.831105
Retained Earnings (Accumulated Deficit) | $								$ (48,478,017)		$ (46,357,373)	$ (35,776,340)
Stockholders' Equity, Reverse Stock Split					the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.		the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.
Interactive Motion Technologies Inc [Member]
Business Acquisition, Equity Interest Issued or Issuable, Number of Shares						157,667
Share Exchange Agreement [Member]
Stock Issued During Period, Shares, New Issues		333,334
Share Exchange Ratio		3.14
Variable Interest Entity, Qualitative or Quantitative Information, Ownership Percentage		100.00%

BASIS OF PRESENTATION (Detail T

BASIS OF PRESENTATION (Detail Textual)	Oct. 29, 2018	Feb. 13, 2015	Oct. 29, 2018	Feb. 13, 2015	Jun. 30, 2019$ / shares	Mar. 31, 2019$ / shares	Mar. 31, 2018$ / shares
Disclosure Text Block [Abstract]
Common Stock, Par or Stated Value Per Share					$ 0.001	$ 0.001	$ 0.001
Stockholders' Equity, Reverse Stock Split			the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.	the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.
Stockholders' Equity Note, Stock Split, Conversion Ratio	0.0067	0.831105

SIGNIFICANT ACCOUNTING POLICI_4

SIGNIFICANT ACCOUNTING POLICIES (Details Textual) - USD ($)	Jun. 30, 2018	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Significant Accounting Policies [Line Items]
Standard and Extended Product Warranty Accrual		$ 168,000	$ 143,500	$ 64,957
Product Warranty Expense	$ 10,108	$ 26,911	$ 84,038
Disclosure on Geographic Areas, Long-Lived Assets			Approximately 99% of the Company’s assets are US-based and all sales for the years ended March 31, 2019 and 2018 were made by the Company’s US subsidiary, Bionik, Inc. In addition, all of the Company’s technology and other assets and goodwill are connected to the acquisition by the Company in April 2016 of Bionik, Inc. Equipment connected to Bionik Inc. amounts to $148,618 (March 31, 2018 -$120,910) and $43,910 (March 31, 2018 - $39,051) is connected to equipment at the Company’s Canadian subsidiary Bionik Laboratories Inc.
Allowance for Doubtful Accounts Receivable			$ 0	19,694
Lessee, Finance Lease, Term of Contract			60 months
Computer And Electronics [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			50.00%
Furniture And Fixtures [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			20.00%
Demonstration Equipment [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			50.00%
Manufacturing Equipment [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			20.00%
Tool and Parts [Member]
Significant Accounting Policies [Line Items]
Percentage Of Depreciated Per Annum			20.00%
Equipment [Member] | CANADA
Significant Accounting Policies [Line Items]
Equipment, Net			$ 43,910	39,051
Equipment [Member] | UNITED STATES
Significant Accounting Policies [Line Items]
Equipment, Net			$ 148,618	$ 120,910

TECHNOLOGY AND OTHER ASSETS (De

TECHNOLOGY AND OTHER ASSETS (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 5,580,704			$ 5,580,704
Amortization of Intangible Assets	69,314	$ 71,053	$ 278,997	323,905
Intangible Assets, Net (Excluding Goodwill)	$ 4,358,408		4,427,722	$ 4,706,719
Patents and exclusive License Agreement [Member]
Finite-Lived Intangible Asset, Useful Life	9 years 8 months 27 days			9 years 8 months 26 days
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,306,031			$ 1,306,031
Amortization of Intangible Assets	33,522		134,126	134,126
Intangible Assets, Net (Excluding Goodwill)	877,918		911,440	$ 1,045,530
Trademark [Member]
Finite Lived Intangible Asset Useful Life Description				Indefinite
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	2,505,907			$ 2,505,907
Amortization of Intangible Assets	0		0	0
Intangible Assets, Net (Excluding Goodwill)	$ 2,505,907		2,505,907	$ 2,505,907
Customer relationships [Member]
Finite-Lived Intangible Asset, Useful Life	10 years			10 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 1,431,680			$ 1,431,680
Amortization of Intangible Assets	35,792		143,206	143,206
Intangible Assets, Net (Excluding Goodwill)	$ 974,583		1,010,375	$ 1,153,543
Non compete agreement [Member]
Finite-Lived Intangible Asset, Useful Life	2 years			2 years
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 61,366			$ 61,366
Amortization of Intangible Assets	0		1,739	30,709
Intangible Assets, Net (Excluding Goodwill)	$ 0		0	$ 1,739
Assembled Workforce [Member]
Finite-Lived Intangible Asset, Useful Life	1 year			1 year
Noncash or Part Noncash Acquisition, Intangible Assets Acquired	$ 275,720			$ 275,720
Amortization of Intangible Assets	0		0	15,864
Intangible Assets, Net (Excluding Goodwill)	$ 0		$ 0	$ 0

TECHNOLOGY AND OTHER ASSETS (_2

TECHNOLOGY AND OTHER ASSETS (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Amortization of Intangible Assets	$ 69,314	$ 71,053	$ 278,997	$ 323,905

PREPAID EXPENSES AND OTHER RE_3

PREPAID EXPENSES AND OTHER RECEIVABLES (Details) - USD ($)		Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Prepaid Expense And Other Receivables [Line Items]
Prepaid expenses and other receivables		$ 75,780	$ 92,170	$ 86,957
Prepaid inventory		939,593	1,144,392	301,104
Prepaid insurance		160,787	66,320	36,497
Sales taxes receivable (i)	[1]	18,567	52,150	9,097
Sales taxes receivable		$ 1,194,727	$ 1,355,032	$ 433,655
[1]	Sales tax receivable represents net harmonized sales taxes (HST) input tax credits receivable from the Government of Canada.

INVENTORIES (Details)

INVENTORIES (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Inventory [Line Items]
Raw materials		$ 0	$ 237,443
Finished goods	$ 582,058	405,682	0
Inventory, Net	$ 582,058	$ 405,682	$ 237,443

INVENTORIES (Details Textual)

INVENTORIES (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Inventory Write-down	$ 62,589	$ 38,860

INVENTORIES (Details)_2

INVENTORIES (Details) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Cost of Goods and Services Sold	$ 336,085	$ 253,163	$ 1,630,166	$ 402,665
Inventory Cost [Member]
Cost of Goods and Services Sold	$ 299,795	$ 237,000

INVENTORIES - Schedule of inven

INVENTORIES - Schedule of inventories (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
INVENTORIES
Finished Goods	$ 582,058	$ 405,682	$ 0

EQUIPMENT (Details Textual)

EQUIPMENT (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Equipment [Line Items]
Depreciation (Note 7)	$ 23,970	$ 17,595	$ 69,212	$ 89,026

EQUIPMENT - Schedule of net equ

EQUIPMENT - Schedule of net equipment (Details) - USD ($)	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Equipment [Line Items]
Equipment, Cost	$ 761,250	$ 718,448	$ 616,669
Accumulated Depreciation	549,890	525,920	456,708
Equipment, Net	211,360	192,528	159,961
Computer and electronics [Member]
Equipment [Line Items]
Equipment, Cost	286,855	286,855	256,505
Accumulated Depreciation	248,357	243,346	223,750
Equipment, Net	38,498	43,509	32,755
Furniture and fixtures [Member]
Equipment [Line Items]
Equipment, Cost	36,795	36,795	36,795
Accumulated Depreciation	29,999	29,648	28,051
Equipment, Net	6,796	7,147	8,744
Demonstration equipment [Member]
Equipment [Line Items]
Equipment, Cost	314,417	271,615	200,186
Accumulated Depreciation	164,363	147,257	105,441
Equipment, Net	150,054	124,358	94,745
Manufacturing Equipment [Member]
Equipment [Line Items]
Equipment, Cost	88,742	88,742	88,742
Accumulated Depreciation	86,353	86,230	85,668
Equipment, Net	2,389	2,512	3,074
Tools and parts [Member]
Equipment [Line Items]
Equipment, Cost	11,422	11,422	11,422
Accumulated Depreciation	7,007	6,779	5,741
Equipment, Net	4,415	4,643	5,681
Assets under capital lease [Member]
Equipment [Line Items]
Equipment, Cost	23,019	23,019	23,019
Accumulated Depreciation	13,811	12,660	8,057
Equipment, Net	$ 9,208	$ 10,359	$ 14,962

NOTES PAYABLE (Details)

NOTES PAYABLE (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Repayment	$ 0	$ (200,000)
Demand Notes payable [Member]
Balance	51,479	330,600
Accrued interest	1,496	8,497
Repayment	(52,975)	(287,618)
Balance	$ 0	$ 51,479

NOTES PAYABLE (Details 1)

NOTES PAYABLE (Details 1) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Accrued Interest					$ 1,290,039
Fair value of warrants					1,394,164
Accretion Expense	$ 1,162,500	$ 0	$ 134,251	$ 3,266,918	1,937,308
Conversion of Principal and Interest					11,651,407
Convertible Debt [Member]
Balance			$ 0	$ 0	2,017,488	$ 0
Additional principal investment					2,999,975	2,000,000
Accrued Interest					1,037,067	17,488
Fair value of warrants					(548,178)
Accretion Expense					548,178
Conversion of Principal and Interest					(6,054,530)
Balance					$ 0	$ 2,017,488

NOTES PAYABLE (Details 2)

NOTES PAYABLE (Details 2) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accrued Interest		$ 1,290,039
Conversion of principal and interest		11,651,407
Convertible Debt One [Member]
Balance	$ 0
Additional principal investment		500,000
Accrued Interest		33,556
Conversion of principal and interest	(533,556)
Balance	$ 0	$ 0

NOTES PAYABLE (Details 3)

NOTES PAYABLE (Details 3) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Accrued Interest		$ 1,290,039
Conversion of principal and interest		11,651,407
Convertible Debt Two [Member]
Balance	$ 0
Additional principal investment		3,611,400
Accrued Interest		201,928
Conversion of principal and interest	(3,813,328)
Balance	$ 0	$ 0

NOTES PAYABLE (Details 4)

NOTES PAYABLE (Details 4) - USD ($)	1 Months Ended	12 Months Ended
	Jul. 20, 2018	Mar. 31, 2019	Mar. 31, 2018
Principal			$ 9,111,375
Interest			1,290,039
Premium		$ 0	1,249,994
Total Conversion Amount			11,651,407
Beneficial Conversion Feature			$ 1,389,129
Number of Shares Converted	683,396	1,247,099	1,249,008
Convertible Notes Payable (December 2016 to December 2017) [Member]
Principal			$ 4,999,975
Interest			1,054,555
Premium			1,249,994
Total Conversion Amount			7,304,523
Beneficial Conversion Feature			$ 762,301
Number of Shares Converted			779,461
Chinese Convertible Loan [Member]
Principal			$ 500,000
Interest			33,556
Premium			0
Total Conversion Amount			533,556
Beneficial Conversion Feature			$ 76,230
Number of Shares Converted			62,629
Convertible Notes Payable (December 2017 to March 2018) [Member]
Principal			$ 3,611,400
Interest			201,928
Premium			0
Total Conversion Amount			3,813,328
Beneficial Conversion Feature			$ 550,598
Number of Shares Converted			406,918

NOTES PAYABLE (Details 5)

NOTES PAYABLE (Details 5) - USD ($)	1 Months Ended		3 Months Ended		12 Months Ended
	Mar. 28, 2019	Jul. 20, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Principal	$ 4,650,000
Accretion expense (Note 8)	$ 1,162,500		$ 0	$ 134,251	$ 3,266,918	$ 1,937,308
Interest						$ 1,290,039
Convertible Debt [Member]
Principal		$ 4,708,306
Beneficial conversion		406,744
Anti-dilution		1,697,674
Fair value of debt		2,603,888
Accretion expense (Note 8)		2,104,418
Interest		24,547
Ending balance		$ 4,732,853

NOTES PAYABLE (Details 6)

NOTES PAYABLE (Details 6) - Convertible Debt [Member]	12 Months Ended
	Mar. 31, 2019USD ($)
At Issuance	$ 2,104,418
Fair value adjustment	(337,923)
Balance allocated to equity on conversion	(1,766,495)
Ending balance at March 31, 2019	0
Beneficial conversion [Member]
At Issuance	406,744
Fair value adjustment	(406,744)
Balance allocated to equity on conversion	0
Ending balance at March 31, 2019	0
Anti-dilution [Member]
At Issuance	1,697,674
Fair value adjustment	68,821
Balance allocated to equity on conversion	(1,766,495)
Ending balance at March 31, 2019	$ 0

NOTES PAYABLE (Details 7)

NOTES PAYABLE (Details 7) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Principal	$ 4,650,000
Accretion expense (Note 8)	1,162,500	$ 0	$ 134,251	$ 3,266,918	$ 1,937,308
Interest	(198,117)	$ (13,283)	$ (36,702)	(255,833)	(1,294,005)
Loan Balance	$ 6,010,617			$ 0	$ 51,479

NOTES PAYABLE (Details Textual)

NOTES PAYABLE (Details Textual)	Aug. 14, 2017	Mar. 28, 2019USD ($)	Jul. 20, 2018USD ($)shares	Jan. 31, 2018	Dec. 31, 2017USD ($)	Jun. 30, 2019USD ($)	Jun. 30, 2018USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)shares	Mar. 31, 2018USD ($)shares	Mar. 31, 2017USD ($)	Feb. 15, 2017USD ($)	Jan. 15, 2017USD ($)	Dec. 31, 2016USD ($)	Feb. 28, 2014USD ($)
Debt Instrument [Line Items]
Interest Rate Per Month					1.50%			1.00%	1.00%
Interest Expense, Debt										$ 1,290,039
Debt Instrument, Face Amount		$ 4,650,000
Debt Instrument, Convertible, Terms of Conversion Feature										In May 2017, the Company’s Chinese joint venture partners loaned the Company $500,000 at an interest rate of 8% convertible into the Company’s common shares upon a capital raise (“Qualified Financing”) where gross proceeds exceed $3,000,000 at the lesser of $0.50 and the quotient of the outstanding balance on the conversion date by the price of the Qualified Financing. Additionally, the holders are entitled to warrants equaling 25% of the number of conversion shares to be issued at conversion. During the year ended March 31, 2018 $33,556 of interest was accrued and expensed on these convertible loans.
Ending balance		$ 6,010,617						$ 0	$ 0	$ 51,479
Interest Expense, Related Party									$ 0	3,200
Repayments of Related Party Debt										3,200
Convertible Notes Payable (December 2016 to December 2017)										4,999,975
Warrants Not Settleable in Cash, Fair Value Disclosure										$ 548,178
Discount on Convertible Loan exercise price		20.00%
Debt Conversion, Converted Instrument, Shares Issued | shares			683,396						1,247,099	1,249,008
Accretion Expense		$ 1,162,500				$ 0	$ 134,251		$ 3,266,918	$ 1,937,308
Proceeds from Notes Payable								4,650,000
Proceeds from Related Party Debt					$ 400,000			$ 1,050,000
Stock Issued During Period, Value, Conversion of Convertible Securities		6,010,617							13,214,092	9,180,785
Interest expense		$ 198,117				$ 13,283	$ 36,702		$ 255,833	$ 1,294,005
Measurement Input, Risk Free Interest Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Measurement Input										1.91
Warrant [Member]
Debt Instrument [Line Items]
Fair Value Measurement Valuation Techniques										binomial valuation model
Warrant [Member] | Measurement Input, Exercise Price [Member]
Debt Instrument [Line Items]
Debt Instrument, Measurement Input										0.25
Warrant [Member] | Measurement Input, Expected Term [Member]
Debt Instrument [Line Items]
Debt Instrument, Measurement Input										5
Warrant [Member] | Measurement Input, Price Volatility [Member]
Debt Instrument [Line Items]
Debt Instrument, Measurement Input										114
Convertible Debt [Member]
Debt Instrument [Line Items]
Interest Expense, Debt										$ 1,037,067	$ 17,488
Debt Instrument, Face Amount											500,000			$ 1,500,000
Debt Instrument, Convertible, Terms of Conversion Feature	upon the consummation of an equity or equity-linked round of with an aggregate gross proceeds of $7,000,000, without any action on part of the Holder, the outstanding principal, accrued and unpaid interest and premium amount equal to 25% of the principal amount less the accrued and unpaid interest, will be converted into shares of new round stock based upon the lesser of (a) the lowest issuance (or conversion) price of new round stock in case there is more than one tranche of new round stock or (b) $0.25.
Proceeds from Contributions from Affiliates										$ 2,999,975	2,000,000
Debt Instrument, Interest Rate Terms										In December 2017, investors of the Company advanced funds under a new convertible loan offering. These convertible loans bear interest at a fixed rate of 3% per month until the earlier of (a) January 31, 2018 and (b) the consummation of a qualified financing defined as gross proceeds of no less than $7,000,000 and up to $14,000,000 raised in one or more tranches.
Accretion Expense										$ 548,178
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Proceeds from Contributions from Affiliates										3,611,400
Convertible Debt One [Member]
Debt Instrument [Line Items]
Interest Rate Per Month								1.00%	1.00%
Interest Expense, Debt										33,556
Proceeds from Contributions from Affiliates										500,000
Debt Instrument, Interest Rate Terms				In January 2018, the terms of the new convertible loan offering were amended to extend the maturity date until March 31, 2018 and in March 2018 the terms of the loans were amended to change the definition of qualified financing as gross proceeds of no less than $2,000,000 and up to $14,000,000 raised in one or more tranches.
Proceeds from Convertible Debt Including Capitalized Interest			$ 4,708,306						$ 9,326,633	7,111,375
Interest Costs Capitalized			31,673
Accretion Expense									3,266,918
Debt Instrument Convertible Conversion feature Fair Value Adjustments									(337,923)
Proceeds from Related Party Debt			2,297,928						3,347,928
Convertible Notes Payable, Noncurrent			$ 4,732,853
Convertible Debt Two [Member]
Debt Instrument [Line Items]
Interest Expense, Debt										201,928
Proceeds from Contributions from Affiliates										3,611,400
Accretion Expense										1,937,308
Second Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount													$ 500,000
Fourth Tranches [Member] | Convertible Debt [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount											2,000,000	$ 500,000
Promissory Note [Member]
Debt Instrument [Line Items]
Notes Payable															$ 200,000
Debt Instrument, Interest Rate, Stated Percentage															10.00%
Interest Expense, Debt									0	12,957
Demand Notes payable [Member]
Debt Instrument [Line Items]
Notes Payable								$ 0	0	51,479	$ 330,600
Interest Expense, Debt									$ 1,496	$ 8,497

NOTES PAYABLE (Details)_2

NOTES PAYABLE (Details) - USD ($)	1 Months Ended	3 Months Ended	12 Months Ended
	Mar. 28, 2019	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018	Jun. 30, 2018
Debt Instrument [Line Items]
Stock Issued During Period, Value, Conversion of Convertible Securities	$ 6,010,617		$ 13,214,092	$ 9,180,785
Convertible note offering			$ 9,000,000
Term Loan [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.00%	1.00%
Proceeds from Sale of Available-for-sale Securities		$ 10,000,000
Accrued interest expense		8,833			$ 0
Director [Member]
Debt Instrument [Line Items]
Convertible loans received		$ 500,000	$ 500,000
Convertible Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Convertible, Conversion Price		$ 6.80
Accrued interest expense		$ 4,450
Convertible Loans Payable [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Debt Instrument [Line Items]
Convertible note offering		$ 9,000,000
Convertible Loans Payable [Member] | Investors [Member]
Debt Instrument [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.00%
Convertible loans received		$ 950,000
Convertible note offering		$ 9,000,000

RELATED PARTY TRANSACTIONS AN_2

RELATED PARTY TRANSACTIONS AND BALANCES (Details Textual) - USD ($)	Mar. 31, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Related Party Transaction [Line Items]
Accrued interest receivable	$ 353	$ 90		$ 353	$ 590
Interest Rate On Loan	2.00%			2.00%	1.00%
Chief Executive Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 229,473	258,737		$ 229,473	$ 208,567
Chief Technology Officer [Member]
Related Party Transaction [Line Items]
Due from Related Parties	18,585	19,068		18,585	18,897
Accounts Payable, Related Parties	14,851	$ 14,532		14,851	135,039
Related Party Transaction, Rate		2.00%	1.00%
Chief Financial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	33,387	$ 33,432		33,387	116,624
Chief Commercial Officer [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	28,025	$ 28,025		28,025	28,025
Board of Directors Chairman [Member]
Related Party Transaction [Line Items]
Accounts Payable, Related Parties	$ 0			$ 0	$ 587,019

SHARE CAPITAL (Details)

SHARE CAPITAL (Details) - USD ($)	1 Months Ended	3 Months Ended		12 Months Ended
	Mar. 28, 2019	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Opening Balance		$ 27,407,933	$ 20,463,014	$ 20,463,014	$ 24,150,650
Shares issued to exchangeable shares	$ 6,010,617			13,214,092	9,180,785
Warrants exercised					1,125,038
Closing Balance		$ 25,575,046	$ 23,941,884	$ 27,407,933	$ 20,463,014
Exchangable Shares [Member]
Opening Balance (in shares)		196,799	295,146	295,146	319,396
Opening Balance		$ 197	$ 295	$ 295	$ 319
Converted into common shares (in shares)				(98,347)	(24,250)
Converted into common shares				$ (98)	$ (24)
Closing Balance (in shares)				196,799	295,146
Closing Balance				$ 197	$ 295
Common Shares [Member]
Opening Balance (in shares)		3,661,838	1,368,856	1,368,856	325,901
Opening Balance		$ 3,661	$ 1,369	$ 1,369	$ 326
Shares issued to exchangeable shares (in shares)				98,347	24,250
Shares issued to exchangeable shares				$ 98	$ 24
Shares issued on conversion of loans (in shares)				2,194,133	985,370
Shares issued on conversion of loans				$ 2,194	$ 986
Warrants exercised (in shares)				0	33,335
Warrants exercised					$ 33
Share consolidation rounding adjustment (iv) (in shares)				502	0
Share consolidation rounding adjustment (iv)				$ 0	$ 0
Closing Balance (in shares)				3,661,838	1,368,856
Closing Balance				$ 3,661	$ 1,369
Exchangeable Shares [Member]
Opening Balance (in shares)		196,799	295,146	295,146
Opening Balance		$ 197	$ 295	$ 295
Converted into common shares (in shares)		(40,560)		(98,347)
Converted into common shares		$ (41)		$ (98)
Closing Balance (in shares)		156,239		196,799	295,146
Closing Balance		$ 156		$ 197	$ 295
Common Shares [Member]
Opening Balance (in shares)		3,661,838	1,368,856	1,368,856
Opening Balance		$ 3,661	$ 1,369	$ 1,369
Shares issued to exchangeable shares (in shares)		40,560		98,347
Shares issued to exchangeable shares		$ 41		$ 98
Shares issued on conversion of loans (in shares)		0		2,194,133
Shares issued on conversion of loans		$ 0		$ 2,194
Share consolidation rounding adjustment (iv) (in shares)		0		502
Share consolidation rounding adjustment (iv)		$ 0		$ 0
Closing Balance (in shares)		3,702,398		3,661,838	1,368,856
Closing Balance		$ 3,661		$ 3,661	$ 1,369
Common Shares And Exchangeable Shares [Member]
Opening Balance (in shares)		3,858,637	1,664,002	1,664,002
Opening Balance		$ 3,858	$ 1,664	$ 1,664
Closing Balance (in shares)		3,858,637		3,858,637	1,664,002
Closing Balance		$ 3,858		$ 3,858	$ 1,664

SHARE CAPITAL (Details Textual)

SHARE CAPITAL (Details Textual) - USD ($)	Mar. 31, 2019	Mar. 28, 2019	Oct. 29, 2018	Jul. 20, 2018	Feb. 13, 2015	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Proceeds from Warrant Exercises								$ 0	$ 1,125,038
Debt Conversion, Original Debt, Amount									9,058,708
Debt Conversion, Original Debt to be Converted, Amount									$ 1,342,705
Debt Conversion, Converted Instrument, Shares to be Issued									263,639
Debt Conversion, Converted Instrument, Value of Shares to be Issued									$ 2,470,622
Loss on Mark to Market Reevaluation						$ 0	$ (2,048,697)	$ (2,048,697)	376,674
Market Value of Shares To Be Issued									$ 2,847,296
Stock Issued During Period, Shares, Exchangeable Shares Exercised	98,347					40,560		98,347	24,250
Stockholders' Equity, Reverse Stock Split			the Company effected a reverse stock split and thereafter Bionik’s common stock began trading on the OTCQB market on a one-for-one hundred and fifty (1:150) split-adjusted basis.		the Company implemented a 1-for-0.831105 reverse stock split of the common stock, which had previously been approved on September 24, 2014.
Fair Value of Exchangeable Options Outstanding									1,451,393
Shares to be Issued, Stock Options and Warrants	$ 0							$ 0	$ 5,692,853
Fair value of warrants									1,394,164
Convertible Debt [Member]
Fair value of warrants									$ (548,178)
Convertible Notes Payable [Member]
Conversion of Stock, Amount Issued		$ 4,848,117		$ 4,708,306
Common Stock [Member]
Stock Issued During Period, Shares, Warrants Exercised									33,335
Stock Issued During Period, Shares, Conversion of Convertible Securities							263,639	263,639
Conversion of Stock, Shares Issued									985,370
Common Stock [Member] | Convertible Debt One [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities				683,395				683,395
Common Stock [Member] | Convertible Debt Two [Member]
Stock Issued During Period, Shares, Conversion of Convertible Securities		1,247,099						1,247,099
Warrant [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights									$ 37.50
Stock Issued During Period, Shares, Warrants Exercised									33,335
Proceeds from Warrant Exercises									$ 1,125,038

SHARE CAPITAL - Additional Info

SHARE CAPITAL - Additional Information (Details)	Mar. 31, 2019shares	Oct. 29, 2018	Feb. 13, 2015	Jun. 30, 2019shares	Mar. 31, 2019shares	Mar. 31, 2018shares
SHARE CAPITAL
Exchangeable shares	98,347			40,560	98,347	24,250
Reverse stock split ratio		0.0067	0.831105

STOCK OPTIONS (Details)

STOCK OPTIONS (Details) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019	Mar. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 37.73	$ 75
Number of Options	344,989	182,996	170,675
Exercisable Options	166,768	111,752
Stock Option One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 34.50	$ 34.50
Number of Options	630	630
Expiry Date	Jun. 20, 2021	Jun. 20, 2021
Exercisable Options	630	630
Stock Option Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 34.50	$ 34.50
Number of Options	13,212	13,212
Expiry Date	Jul. 1, 2021	Jul. 1, 2021
Exercisable Options	13,212	13,212
Stock Option Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 34.50	$ 34.50
Number of Options	944	944
Expiry Date	Feb. 17, 2022	Feb. 17, 2022
Exercisable Options	944	944
Stock Option Four [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 183	$ 183
Number of Options	2,667	2,667
Expiry Date	Nov. 24, 2022	Nov. 24, 2022
Exercisable Options	2,667	2,667
Stock Option Five [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 150	$ 150
Number of Options	11,400	11,400
Expiry Date	Dec. 14, 2022	Dec. 14, 2022
Exercisable Options	11,400	11,400
Stock Option Six [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 142.50	$ 142.50
Number of Options	359	359
Expiry Date	Mar. 28, 2023	Mar. 28, 2023
Exercisable Options	359	359
Stock Option Seven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 157.50	$ 157.50
Number of Options	1,387	1,387
Expiry Date	Mar. 28, 2023	Mar. 28, 2023
Exercisable Options	1,387	1,387
Stock Option Eight [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 150
Number of Options		1,112
Expiry Date		Apr. 26, 2023
Exercisable Options		1,112
Stock Option Eight February 2024 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 105	$ 105
Number of Options	2,667	2,667
Expiry Date	Feb. 6, 2024	Feb. 6, 2024
Exercisable Options	1,778	1,778
Stock Option Nine [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 102	$ 102
Number of Options	1,667	1,667
Expiry Date	Feb. 13, 2024	Feb. 13, 2024
Exercisable Options	1,667	1,667
Stock Option Ten [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 142.50	$ 142.50
Number of Options	106	106
Expiry Date	Mar. 3, 2024	Mar. 3, 2024
Exercisable Options	106	106
Stock Option Eleven [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 157.50	$ 157.50
Number of Options	408	408
Expiry Date	Mar. 3, 2024	Mar. 3, 2024
Exercisable Options	408	408
Stock Option Twelve [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 142.50	$ 142.50
Number of Options	43	43
Expiry Date	Mar. 14, 2024	Mar. 14, 2024
Exercisable Options	43	43
Stock Option Thirteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 157.50	$ 157.50
Number of Options	164	164
Expiry Date	Mar. 14, 2024	Mar. 14, 2024
Exercisable Options	164	164
Stock Option Fourteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 142.50	$ 142.50
Number of Options	485	485
Expiry Date	Sep. 30, 2024	Sep. 30, 2024
Exercisable Options	485	485
Stock Option Fifteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 157.50	$ 157.50
Number of Options	1,876	1,876
Expiry Date	Sep. 30, 2024	Sep. 30, 2024
Exercisable Options	1,876	1,876
Stock Option Sixteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 142.50
Number of Options		24
Expiry Date		Jun. 2, 2025
Exercisable Options		24
Stock Option Sixteen September 2027 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 24.15
Number of Options	81,436
Expiry Date	Sep. 1, 2027
Exercisable Options	27,148
Stock Option Seventeen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 157.50
Number of Options		90
Expiry Date		Jun. 2, 2025
Exercisable Options		90
Stock Option Seventeen January 2025 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 23.25
Number of Options	15,656
Expiry Date	Jan. 24, 2025
Exercisable Options	5,867
Stock Option Eighteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 37.50
Number of Options		221
Expiry Date		Dec. 30, 2025
Exercisable Options		221
Stock Option Eighteen April 2028 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 9.735
Number of Options	40,000
Expiry Date	Apr. 19, 2028
Exercisable Options	40,000
Stock Option Nineteen [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 142.50
Number of Options		164
Expiry Date		Dec. 30, 2025
Exercisable Options		164
Stock Option Nineteen May 2026 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price	$ 3.16
Number of Options	169,882
Expiry Date	May 31, 2026
Exercisable Options	56,627
Stock Option Twenty [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 24.150
Number of Options		81,436
Expiry Date		Sep. 1, 2027
Exercisable Options		27,148
Stock Option Twenty One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 23.250
Number of Options		16,934
Expiry Date		Jan. 24, 2025
Exercisable Options		5,867
Stock Option Twenty Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 9.735
Number of Options		40,000
Expiry Date		Apr. 19, 2028
Exercisable Options		40,000
Stock Option Twenty Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price		$ 6.930
Number of Options		5,000
Expiry Date		Jun. 10, 2025
Exercisable Options		0

STOCK OPTIONS (Details 1)

STOCK OPTIONS (Details 1)	12 Months Ended
	Mar. 31, 2019USD ($)
February 17, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	2 years 10 months 20 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 136,613
July 1, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	2 years 3 months
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,259,487
June 20, 2014 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	2 years 2 months 19 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 118,957
November 24 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 7 months 24 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 694,384
December 14, 2015 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	3 years 8 months 15 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,260,437
April 21, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 1 month 9 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 2,582,890
April 26, 2016 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 25 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 213,750
February 6, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 10 months 9 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 245,200
February 13, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	4 years 10 months 17 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 148,750
September 1, 2017 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	8 years 5 months 4 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 1,832,304
January 24, 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	5 years 9 months 25 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 491,036
April 30 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	9 years 21 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 363,714
June 11 2018 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life in years	6 years 2 months 12 days
Risk free rate	1.59%
Dividend rate	0.00%
Forfeiture rate	0.00%
Expected volatility	114.00%
Grant date fair value	$ 30,341

STOCK OPTIONS (Details 2)

STOCK OPTIONS (Details 2) - $ / shares	Jan. 24, 2018	Jun. 30, 2019	Mar. 31, 2019
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number Options, Outstanding, Beginning Balance (in shares)		182,996	170,675
Number of Options, Issued (in shares)	24,267		45,000
Number of Options, Cancelled (in shares)			(32,679)
Number of Options, Outstanding, Ending Balance (in shares)		344,989	182,996
Weighted-Average Exercise Price, Outstanding, Beginning Balance (in dollars per share)		$ 37.73	$ 75
Weighted-Average Exercise Price, Issued (in dollars per share)			9.42
Weighted-Average Exercise Price, Cancelled (in dollars per share)			65.93
Weighted-Average Exercise Price, Outstanding, Ending Balance (in dollars per share)			$ 37.73

STOCK OPTIONS (Details Textual)

STOCK OPTIONS (Details Textual) - USD ($)	May 31, 2019	Jun. 11, 2018	Jun. 11, 2018	Apr. 30, 2018	Jan. 24, 2018	Sep. 01, 2017	Sep. 01, 2017	Feb. 06, 2017	Feb. 06, 2017	Apr. 26, 2016	Dec. 14, 2015	Apr. 30, 2018	Jan. 24, 2018	Aug. 03, 2017	Feb. 13, 2017	Aug. 08, 2016	Apr. 26, 2016	Apr. 21, 2016	Nov. 24, 2015	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Maximum percentage of common stock and exchangeable shares issued and outstanding that may be reserved for issuance upon exercise of all options or other securities granted																				15.00%
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross					24,267																	45,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																						$ 9.42
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																						32,679
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number																				344,989		182,996	170,675
Allocated Share-based Compensation Expense																				$ 28,554	$ 39,703	$ 140,540	$ 27,280
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term																				6 years 5 months 27 days	7 years 10 months 21 days	7 years 2 months 12 days	7 years 5 months 15 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term																				6 years 4 months 10 days	7 years 4 months 17 days	6 years 9 months 18 days	5 years 8 months 26 days
Fair Value Of Options					$ 491,036
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period																						7 years
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense																				$ 287,757	$ 595,412	$ 1,347,399	$ 1,540,580
Employees Of Bionik Inc [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross										1,667								20,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price										$ 150							$ 150
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																	1,667					557	0
Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number																		3,895,000
Allocated Share-based Compensation Expense																				$ 3,431	17,813	$ 63,333	$ 71,250
Fair Value Of Options										$ 213,750							$ 213,750	$ 2,582,890
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period										3 years
Employees Of Bionik Inc [Member] | Exercise Price Range One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																		$ 37.50
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period																		6,667
Employees Of Bionik Inc [Member] | Exercise Price Range Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																		$ 142.50
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period																		6,667
Employees Of Bionik Inc [Member] | Exercise Price Range Three [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																		$ 157.50
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period																		6,666
Employees Of Bionik Inc [Member] | Unvested option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Allocated Share-based Compensation Expense																						$ 0	$ 29,524
Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																			4,334
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																			$ 183
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																			1,667	778		7,334	0
Allocated Share-based Compensation Expense																						$ 92,585	$ 142,438
Fair Value Of Options																			$ 694,384
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																			3 years
Employee One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross																5,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price																$ 150
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																						3,335
Allocated Share-based Compensation Expense																						$ 48,301	$ 217,356
Fair Value Of Options																$ 652,068
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period																3 years
Director And Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 3.16
Allocated Share-based Compensation Expense																				$ 176,394
Fair Value Of Options	$ 453,585
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	169,882
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate	1.59%
Director And Employees [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	6 months
Director And Employees [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period	1 year
Director and Employees and Consultant One [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross											16,634
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price											$ 150
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period																						1,889	2,912	434
Allocated Share-based Compensation Expense																						$ 105,121	$ 479,315
Fair Value Of Options											$ 1,260,437
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period						5 years					3 years
Employee Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross								2,667	2,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price								$ 105	$ 105
Allocated Share-based Compensation Expense																				20,433	20,433	81,733	81,733
Fair Value Of Options								$ 245,200	$ 245,200
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period								3 years	3 years
Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross															1,667
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price															$ 102
Allocated Share-based Compensation Expense																						92,821	49,583
Fair Value Of Options															$ 148,750
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period															1 year 6 months
Executive Employee [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross														13,334
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price														$ 31.50
Allocated Share-based Compensation Expense																						7,546	60,371
Fair Value Of Options														$ 387,209
Share Based Compensation Arrangement By Share Based Payment Award Additional Options Grants In Period Gross														10,000
Executive Employee And Consultant [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross						81,436	81,436
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price						$ 24.15	$ 24.15
Allocated Share-based Compensation Expense																				57,259	38,173	343,557	$ 381,730
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							50.00%
Fair Value Of Options						$ 1,832,304	$ 1,832,304
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares							27,148
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights						50% of the remaining options vest on performance being met and 50% vest annually over 5 years for the CEO, for our Chairman the options vest over 5 years.
Executive Employee And Consultant [Member] | Share-based Payment Arrangement, Tranche Two [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Rights, Percentage							50.00%
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period							5 years
New Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		5,000	5,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price		$ 6.93	$ 6.93
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period			5,000
Allocated Share-based Compensation Expense																				$ 1,686	$ 562	$ 8,147
Fair Value Of Options		$ 30,341	$ 30,341
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period			3 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term		7 years	7 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate		114.00%	114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate		1.59%	1.59%
Executive Officer [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross				40,000								40,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price				$ 9.74								$ 9.74
Allocated Share-based Compensation Expense				$ 363,714								$ 363,714
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period				10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term				10 years								10 years
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate				114.00%								114.00%
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate				1.59%								1.59%
Employees vest equally on January 24, 2019 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 23.25								$ 23.25
Employees vest equally on January 24 2020 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					23.25								23.25
Employees Vest Equally On January242021 [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 23.25								$ 23.25

WARRANTS (Details)

WARRANTS (Details) - $ / shares	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Number of Warrants, Outstanding and exercisable, Beginning balance	288,517	365,974	365,974	117,589
Number of Warrants, Expired	(163,483)	0	(204,304)
Number of Warrants, Outstanding and exercisable, Ending balance	125,034		288,517	365,974
Weighted-Average Exercise Price, Outstanding and exercisable, Beginning balance	$ 40.27	$ 53.19	$ 53.19	$ 202.50
Weighted-Average Exercise Price, Issued				112.35
Weighted-Average Exercise Price, Outstanding and exercisable, Ending balance	20.07	$ 53.19	40.27	$ 53.19
Weighted-Average Exercise Price, Expired	$ (38.91)		$ (51.85)
Class of Warrant or Right, Number of Warrants	125,034		288,517
Broker [Member]
Number of Warrants, Issued				2,667
Weighted-Average Exercise Price, Issued				$ 37.50
Warrants Exercised [Member]
Number of Warrants, Exercised				(33,335)
Weighted-Average Exercise Price, Exercised				$ (37.50)
Warrant One [Member]
Number of Warrants, Issued			67,952	559
Weighted-Average Exercise Price, Issued			$ 55.71	$ 112.35
Warrant One [Member]
Warrant exercise price	$ 90		$ 90
Class of Warrant or Right, Number of Warrants	15,658		15,658
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023		Mar. 31, 2023
Warrant Two [Member]
Warrant exercise price	$ 37.50		$ 38.91
Class of Warrant or Right, Number of Warrants	2,667		84,562
Class Of Warrant Or Right Expiry Date	Jun. 27, 2020		Apr. 21, 2019
Warrant Two [Member]
Number of Warrants, Issued			6,305	6,275
Weighted-Average Exercise Price, Issued			$ 34.50	$ 194
Warrant Three [Member]
Number of Warrants, Issued			52,590	13,464
Weighted-Average Exercise Price, Issued			$ 38.91	$ 44.28
Warrant3 [Member]
Warrant exercise price	$ 9.375		$ 38.91
Class of Warrant or Right, Number of Warrants	64,025		39,922
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022		May 27, 2019
Warrant Four [Member]
Number of Warrants, Issued				136,388
Weighted-Average Exercise Price, Issued				$ 73.02
Warrant exercise price	$ 9.375		$ 38.91
Class of Warrant or Right, Number of Warrants	42,684		38,998
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022		Jun. 30, 2019
Warrant Five [Member]
Number of Warrants, Issued			67,952
Weighted-Average Exercise Price, Issued			$ 55.71
Warrant exercise price			37.50
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 37.50
Class of Warrant or Right, Number of Warrants			2,667
Class Of Warrant Or Right Expiry Date			Jun. 27, 2020
Warrant Six [Member]
Number of Warrants, Issued			6,305
Weighted-Average Exercise Price, Issued			$ 34.50
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 9.375
Class of Warrant or Right, Number of Warrants			64,025
Class Of Warrant Or Right Expiry Date			Aug. 14, 2022
Warrant Seven [Member]
Class of Warrant or Right, Exercise Price of Warrants or Rights			$ 9.375
Class of Warrant or Right, Number of Warrants			42,684
Class Of Warrant Or Right Expiry Date			Mar. 31, 2022
Common Shares One [Member]
Number of Warrants, Issued				106,709
Weighted-Average Exercise Price, Issued				$ 9.375
Common Shares Two [Member]
Number of Warrants, Issued				15,658
Weighted-Average Exercise Price, Issued				$ 90

WARRANTS (Details 1)

WARRANTS (Details 1) - $ / shares	3 Months Ended	12 Months Ended
	Jun. 30, 2019	Mar. 31, 2019
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	125,034	288,517
Warrant One [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	15,658	15,658
Class Of Warrant Or Right Expiry Date	Mar. 31, 2023	Mar. 31, 2023
Warrant exercise price	$ 90	$ 90
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	2,667	84,562
Class Of Warrant Or Right Expiry Date	Jun. 27, 2020	Apr. 21, 2019
Warrant exercise price	$ 37.50	$ 38.91
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	64,025	39,922
Class Of Warrant Or Right Expiry Date	Aug. 14, 2022	May 27, 2019
Warrant exercise price	$ 9.375	$ 38.91
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Number of Warrants	42,684	38,998
Class Of Warrant Or Right Expiry Date	Mar. 31, 2022	Jun. 30, 2019
Warrant exercise price	$ 9.375	$ 38.91
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 37.50
Class of Warrant or Right, Number of Warrants		2,667
Class Of Warrant Or Right Expiry Date		Jun. 27, 2020
Warrant exercise price		$ 37.50
Warrant Six [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 9.375
Class of Warrant or Right, Number of Warrants		64,025
Class Of Warrant Or Right Expiry Date		Aug. 14, 2022
Warrant Seven [Member]
Class of Warrant or Right [Line Items]
Class of Warrant or Right, Exercise Price of Warrants or Rights		$ 9.375
Class of Warrant or Right, Number of Warrants		42,684
Class Of Warrant Or Right Expiry Date		Mar. 31, 2022

WARRANTS (Details Textual)

WARRANTS (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2017
Class of Warrant or Right [Line Items]
Share Based Compensation Arrangement By Share Based Payments Award Non Options Exercised Weighted Average Exercise Price	$ 20.07	$ 53.19	$ 40.27	$ 53.19	$ 202.50
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms	3 years 26 days	2 years 4 days	1 year 6 months 3 days	2 years 3 months 7 days
Proceeds from Warrant Exercises			$ 0	$ 1,125,038
Anti-dilution Loss			$ 0	$ 0
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued				$ 112.35
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Expirations	163,483	0	204,304
Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share based Compensation Arrangement By Share based Payment Award Equity Instruments Other Than Options Granted Weighted Average Exercise Price Issued			$ 73.02
Warrant One [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				559
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 90
Warrants Issued				15,658
Class of Warrant or Right Expiration years				5 years
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued			120
Warrant One [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 120
Warrant Two [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 194
Warrants Issued				6,275
Warrant Two [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price			$ 210	$ 210
Warrant Three [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted			52,590	13,464
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued			$ 38.91	$ 44.28
Warrant Four [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted				136,388
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued				$ 73.02
Warrant Nine [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 37.50
Warrants Issued				2,667
Warrant Ten and Eleven [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price				$ 9.375
Warrants Issued				106,709
Warrant Twelve [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price			55.71
Warrant Twelve [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price			$ 73.02
Warrant Thirteen [Member]
Class of Warrant or Right [Line Items]
Warrants Issued			6,305
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued			$ 34.50
Warrant Thirteen [Member] | Previously Reported [Member]
Class of Warrant or Right [Line Items]
Share Based Compensaction Arrangement By Share Based Payment Award Non Options Exercised Weighted Average Exercise Price			$ 44.28
Warrant Five [Member]
Class of Warrant or Right [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted			67,952
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Weighted Average Exercise Price Issued			$ 55.71
Retained Earnings [Member]
Class of Warrant or Right [Line Items]
Anti-dilution Loss			$ (24,432)	$ (74,086)

INCOME TAXES (Details)

INCOME TAXES (Details) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Components of net loss before income taxes consists of the following:
U.S.	$ (8,849,294)	$ (12,281,398)
Canada	(1,707,307)	(2,344,392)
Net (loss) for the year before recovery of income taxes	$ (10,556,601)	$ (14,625,790)
Statutory rate	25.30%	34.04%
Expected income tax (recovery) expense	$ (2,670,579)	$ (4,978,619)
Tax rate changes and other basis adjustments	(525,472)	1,748,278
Stock-based compensation	340,861	524,412
Difference in Foreign Tax Rates	0	0
Accretion	890,797	184,414
Change in fair value	(85,487)	659,458
(Gain) loss on mark to market re-evaluation	(518,274)	0
Share premium	0	425,497
Non-deductible expense	83,578	339,296
Net DTA acquired	0	0
Change in valuation allowance	2,484,576	1,097,264
Recovery of income taxes	$ 0	$ 0

INCOME TAXES (Details 1)

INCOME TAXES (Details 1) - USD ($)	Mar. 31, 2019	Mar. 31, 2018
Equipment	$ 70,650	$ 70,350
Share issue costs	0	510
SR&ED pool	844,001	690,320
Other	1,022,309	535,510
Non-capital losses - Canada	2,796,469	2,515,170
Net operating losses - U.S.	5,911,320	4,331,850
Valuation allowance	(9,502,006)	(7,017,430)
Deferred Tax Liabilities, Net, Total	1,142,743	1,126,280
Deferred Tax Assets, Net	(1,142,743)	(1,126,280)
Intangibles and other	$ 0	$ 0

INCOME TAXES (Details 2)

INCOME TAXES (Details 2)	12 Months Ended
	Mar. 31, 2019
Domestic Tax Authority [Member] | United States - Federal [Member]
Income Tax Examination Open Tax Years	2015 – present
Domestic Tax Authority [Member] | United States - State [Member]
Income Tax Examination Open Tax Years	2015 – present
Foreign Tax Authority [Member] | Canada - Federal [Member]
Income Tax Examination Open Tax Years	2014 – present
Foreign Tax Authority [Member] | Canada - Provincial [Member]
Income Tax Examination Open Tax Years	2014 – present

INCOME TAXES (Details Textual)

INCOME TAXES (Details Textual)	Mar. 31, 2019USD ($)
U.S Subsidiary Company [Member]
Operating Loss Carryforwards	$ 14,190,773
Canada [Member]
Operating Loss Carryforwards	10,552,713
U.S parent Company [Member]
Operating Loss Carryforwards	$ 14,190,773

RISK MANAGEMENT (Details Textua

RISK MANAGEMENT (Details Textual) - USD ($)	12 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
Sales Revenue, Net [Member] | Customer One [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	83.30%	88.10%
Sales Revenue, Net [Member] | Customer Two [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	8.90%	1.90%
Sales Revenue, Net [Member] | Customer Three [Member]
Concentration Risk [Line Items]
Concentration Risk, Percentage	4.60%	1.50%
Canada [Member]
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 100,000
UNITED STATES
Concentration Risk [Line Items]
Cash, FDIC Insured Amount	$ 250,000

COMMITMENTS AND CONTINGENCIES (

COMMITMENTS AND CONTINGENCIES (Details Textual) - USD ($)	Feb. 25, 2015	May 17, 2017	May 17, 2017	Feb. 25, 2015	Jun. 30, 2019	Mar. 31, 2019
Stock Issued During Period, Shares, New Issues	1,753
Loan received and repaid	$ 241,185
Description Of Contribution For Formation		Under the terms of the JV Contract, the JV Partner is required to contribute $290,000 within 30 days of formation, $435,000 12 months later and $725,000 60 months after the date of formation. The Company is required to license certain intellectual property to the China JV.
Percentage of Royalty on Sales					1.00%
Royalty on Sales,Percentage						1.00%
Value of the loan	$ 210,323
Bionik Laboratories Corp. [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		25.00%	25.00%
Ginger Capital Investment Holding Inc. [Member]
Equity Method Investment, Ownership Percentage		75.00%	75.00%
China Based Joint Venture [Member]
Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners		25.00%	25.00%
Co Venturer [Member]
Contribution required from JV Partner within 30 days of joint venture formation			$ 290,000
Contribution required from JV Partner 12 months after joint venture formation			435,000
Contribution Required From Partner Sixty Months After Joint Venture Formation			$ 725,000
Co Venturer [Member] | China Based Joint Venture [Member]
Equity Method Investment, Ownership Percentage		75.00%	75.00%
Exchangable Shares [Member]
Stock Issued During Period, Shares, Issued for Services				1,753
Stock Transferred To Lenders				2,098
Stock to be Reimbursed to Officers				2,134
Loan received				$ 241,185
Value of the loan				$ 210,323
Former Chief Technology Officer And New Chief Technology Officer [Member]
Stock Transferred To Lenders	2,098
Stock to be Reimbursed to Officers	2,134

SUBSEQUENT EVENTS (Details Text

SUBSEQUENT EVENTS (Details Textual) - USD ($)	Jan. 24, 2018	Mar. 31, 2019	Jun. 30, 2019
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	24,267	45,000
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period		7 years
Convertible note offering		$ 9,000,000
Term Loan [Member]
Subsequent Event [Line Items]
Debt Instrument, Interest Rate, Stated Percentage		1.00%	1.00%
Debt Instrument, Maturity Date		May 8, 2021
Pre Split Exchangeable Shares [Member]
Subsequent Event [Line Items]
Conversion of Stock, Shares Issued		40,560
Conversion of Stock, Shares Converted pre-split		6,083,900
Director [Member]
Subsequent Event [Line Items]
Term loan		$ 500,000	$ 500,000
Shareholder [Member]
Subsequent Event [Line Items]
Convertible debt		$ 200,000
Board Members and Employees [Member]
Subsequent Event [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		169,882
Shares Issued, Price Per Share		$ 3.16

SUBSEQUENT EVENTS - Additional

SUBSEQUENT EVENTS - Additional Information (Details) - USD ($)	Jul. 01, 2019	Jan. 24, 2018	Jun. 30, 2019	Jun. 30, 2018	Mar. 31, 2019	Mar. 31, 2018
Subsequent Event [Line Items]
Convertible loans			$ 950,000	$ 2,934,298	$ 9,326,633	$ 7,111,375
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross		24,267			45,000
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price					$ 9.42
Subsequent Event [Member]
Subsequent Event [Line Items]
Convertible loans	$ 4,560,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross	495,319
Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price	$ 3.595